Improving malaria case management with artemisinin-based combination therapies and malaria rapid diagnostic tests in private medicine retail outlets in sub-Saharan Africa: a systematic review

Short title (max 100 characters): Improving malaria case management in retail outlets in sub-Saharan Africa: a systematic review

3 May 2023

Authors: Catherine Goodman<sup>1\*</sup>, Sarah Tougher<sup>1</sup>, Terrissa Jing Shang<sup>1</sup>, Theodoor Visser<sup>2</sup>

<sup>1</sup> Department for Global Health and Development. London School of Hygiene and Tropical Medicine, London, UK

<sup>2</sup> Clinton Health Access Initiative, Inc. (CHAI), Global Malaria, Boston, USA

\* Corresponding author

Email: <a href="mailto:catherine.goodman@lshtm.ac.uk">catherine.goodman@lshtm.ac.uk</a> (CG)

## 1 Abstract

#### 2

3 Private medicine retailers (PMRs) such as pharmacies and drug stores account for a substantial share 4 of treatment-seeking for fever and malaria, but there are widespread concerns about quality of care, 5 including inadequate access to malaria rapid diagnostic tests (RDTs) and artemisinin-based 6 combination therapies (ACTs). This review synthesizes evidence on the effectiveness of interventions 7 to improve malaria case management in PMRs in sub-Saharan Africa (PROSPERO 8 #2021:CRD42021253564). We included quantitative studies evaluating interventions supporting RDT 9 and/or ACT sales by PMR staff, with a historical or contemporaneous control group, and outcomes 10 related to care received. We searched Medline Ovid, Embase Ovid, Global Health Ovid, Econlit Ovid 11 and the Cochrane Library; unpublished studies were identified by contacting key informants. We 12 conducted a narrative synthesis by intervention category. We included 41 papers, relating to 34 studies. There was strong evidence that small and large-scale ACT subsidy programmes (without RDTs) 13 14 increased the market share of quality-assured ACT in PMRs, including among rural and poorer groups, 15 with increases of over 30 percentage points in most settings. Interventions to introduce or enhance 16 RDT use in PMRs led to RDT uptake among febrile clients of over two-thirds and dispensing according 17 to RDT result of over three quarters, though some studies had much poorer results. Introducing 18 Integrated Community Case Management (iCCM) was also effective in improving malaria case 19 management. However, there were no eligible studies on RDT or iCCM implementation at large scale. 20 There was limited evidence that PMR accreditation (without RDTs) increased ACT uptake. Key 21 evidence gaps include evaluations of RDTs and iCCM at large scale, evaluations of interventions 22 including use of digital technologies, and robust studies of accreditation and other broader PMR 23 interventions.

# 24 Introduction

25 Malaria remains a leading cause of the burden of disease in Africa, accounting for an estimated 228 26 million cases and 602 000 deaths in 2020, around 95% of global malaria cases and deaths [1]. The past 27 10-15 years have witnessed considerable progress in case management of malaria, particularly 28 through the introduction of highly effective artemisinin-based combination therapies (ACTs) as first-29 line treatment, and the expansion of parasitological diagnosis. Since 2010 the World Health 30 Organisation (WHO) has recommended parasitological diagnosis for every suspected malaria case, as clinical malaria is indistinguishable from the early stages of many other diseases, meaning that reliance 31 32 on clinical diagnosis alone leads to a substantial proportion of patients being treated with antimalarials 33 when their illness has a non-malarial cause [2]. The feasibility of parasitological diagnosis has also been 34 substantially enhanced by the introduction of malaria rapid diagnostic tests (RDTs) which are quick 35 (<20 min), accurate, simple to use, and relatively inexpensive [3].

36 While ACTs and RDTs have been widely adopted in public healthcare facilities across Africa [4], 37 coverage remains inadequate in the private sector, which accounts for a high proportion of treatment 38 seeking for malaria and fever. Among febrile children under 5 for whom care was sought, 30.8% sought 39 care in the private sector based on household surveys conducted between 2015-19 [1], and the 40 percent is likely higher in older age groups. Private sector use is particularly high in some of the highest malaria burden countries in sub-Saharan Africa, accounting for over 50% of treatment seeking for sick 41 42 children in Nigeria, Uganda, and Tanzania [5]. The private sector includes private facilities (such as 43 clinics and hospitals) and private medicine retailers (PMRs). PMRs encompass both retail pharmacies 44 that should be staffed by someone with a pharmacy qualification, and drug shops with less qualified 45 staff, that are allowed to sell a more limited range of medicines, variously known as patent medicine 46 vendors, over-the-counter medicine sellers or dépôts de médicaments. In some settings, medicines 47 are also available through general stores, market stalls and hawkers. PMRs account for a substantial share of private sector treatment seeking for fever, accounting for example for over 60% of private
sector visits for sick children in Tanzania, the Democratic Republic of Congo (DRC), and Nigeria [5].

50 There are widespread concerns about the quality of malaria case management received from PMRs. 51 Febrile patients treated through PMRs typically receive no parasitological diagnosis, as microscopy is 52 not feasible in retail settings and RDT availability is very patchy [6]. Although in most countries with 53 high private sector use some ACTs can legally be sold without a prescription in pharmacies and drug 54 stores [7], in practice, patients often purchase less effective antimalarials or no antimalarial treatment 55 [8]. In addition, there are concerns around the quality of ACTs [9], lack of referral to public sector 56 facilities, inappropriate use of antibiotics, and the failure to include malaria cases treated by PMRs in 57 national surveillance data [10].

58 A range of strategies have been developed to address these concerns. In the pre-ACT era, programmes 59 typically involved some combination of PMR training, job aids, pre-packaging of tablets, and social 60 marketing, with occasional use of accreditation and franchising [11]. With the introduction of ACTs, 61 which were initially substantially more expensive than more commonly used antimalarials such as 62 chloroquine, more radical action was taken to reduce ACT prices in the private sector. ACTs were 63 distributed with a significant subsidy with the intent of reducing retail prices for patients, and thus 64 increasing ACT demand and crowding out other, often less effective, antimalarials. ACT subsidies 65 began through small-scale pilots, but were then adopted on a massive scale under the Affordable 66 Medicine Facility-malaria (AMFm). The AMFm was established by the Global Fund to Fight AIDS, 67 Tuberculosis and Malaria, covering 7 African countries: Ghana, Kenya, Madagascar, Niger, Nigeria, 68 Uganda, and Tanzania from 2010-12 [12, 13]. It subsidised guality-assured ACTs, defined as those pre-69 qualified by WHO or approved by Stringent Regulatory Authorities. Following this period, the Global 70 Fund continued private sector ACT subsidies through the private sector co-payment mechanism (CPM) 71 in six countries [8]. Unlike the AMFm which had earmarked funding, countries were required to 72 allocate funds to the CPM from their core Global Fund malaria grant.

In parallel, various groups began testing interventions to introduce RDTs in PMRs [14]. Other groups focused more broadly on treatment of childhood illness, adapting Integrated Community Case Management (iCCM) guidelines for the treatment of malaria, pneumonia and diarrhoea for drug stores [15, 16]. A few countries, beginning with Tanzania, implemented large-scale accreditation schemes for PMRs, including sales of subsidised ACTs [17].

78 More recent years have seen fewer large-scale PMR malaria interventions in sub-Saharan Africa, but 79 there is currently renewed interest in this topic among national and multilateral organizations [18, 80 19], reflecting the continued high treatment seeking rates in this sector. As no comprehensive, up-to-81 date systematic review was identified on strategies to improve care of febrile patients by PMR, WHO 82 commissioned this review. The objective was to synthesize the evidence on the effect of interventions 83 relating to malaria case management on improving care received from PMRs in sub-Saharan Africa, 84 based on evaluations with a historical or contemporaneous control group. It updates the review by Visser et al on RDT introduction in PMRs [14], while also broadening the scope to consider any 85 intervention relevant to malaria case management. 86

87

# 88 Methods

### 89 Eligibility Criteria

90 This systematic review followed the 2015 PRISMA-p guidelines and was registered on PROSPERO
91 (2021: CRD42021253564) where the protocol can be accessed.

We included studies conducted in sub-Saharan Africa only, reflecting the high malaria burden of many of these countries. While there is considerable literature on malaria case management in PMRs from outside Africa, particularly from the Greater Mekong Subregion [20], we focus on sub-Saharan Africa given the substantial differences in malaria epidemiology and retail market structure between regions. 96 We included all published and unpublished randomized and non-randomized controlled trials, pre-97 post designs with or without a control group, and time-series or repeated measure surveys, that 98 reported on an intervention to support the provision of RDTs and/or ACTs by PMR staff. We included 99 evaluations of both malaria-specific interventions and broader interventions that encompass ACTs or 100 RDTs. Studies that did not report on original research, such as opinion pieces and literature reviews, 101 were excluded, as were reports or conference abstracts with insufficient methodological detail.

102 We defined PMRs as pharmacies, drug stores and any other for-profit private sector retailer supplying 103 medicines. Studies that only reported on for-profit healthcare facilities such as clinics, health centers, 104 and hospitals, not-for-profit providers or community health workers were excluded. To be eligible, 105 studies must have reported on at least one of our primary outcomes, which comprised any 106 measurement of the effect of an intervention on ACT and RDT uptake, dispensing treatment according 107 to test results, referral on the basis of protocol, patient adherence to the treatment regimen, antibiotic 108 uptake, antimalarial quality, and health outcomes (further details provided below). These outcomes 109 were selected as they relate directly to the care received by users, as opposed to intermediate 110 outcomes such as staff knowledge, product availability or price.

We included studies where data were collected between January 2006 and March 2023. The time frame was chosen because prior to 2006, PMR interventions did not involve ACTs or RDTs, and therefore their findings are expected to be less applicable to the current context.

## 114 Search Strategy

A systematic literature search for published studies was conducted on March 10<sup>th</sup>, 2023, in Medline Ovid, Embase Ovid, Global Health Ovid, Cochrane Library and Econlit Ovid. The search terms were synonyms, related terms and MESH terms for five domains (i) 'malaria and fever' (ii) 'PMRs' (iii) 'diagnosis and treatment' (iv) 'antimalarials' and (v) 'Sub-Saharan Africa' (see full search strategy in S1 Table). The search terms were strategically combined, and their performance tested by comparing a list of pre-identified eligible papers to the search results. The results were then filtered by the time limit (Jan 2006-March 2023) and language (English and French). The results of the final searches were exported into Covidence, and duplicates removed.

Covidence was used for independent screening by two authors (ST & TJS). Title and abstracts were screened to identify papers that reported on interventions pertaining to ACT and/or RDT within the private sector, with studies excluded that did not meet the study design criteria. For papers meeting the screening criteria, a full-text review was conducted to determine eligibility. Discrepancies were resolved by discussion and consultation with a third author (CG). Reference lists of all included studies and of earlier related literature reviews [11, 14-16, 21-23] were examined to check for additional papers not captured in the search.

Unpublished studies were identified by contacting researchers and practitioners in the field; a full-text
 review was conducted independently by ST and CG to identify eligible studies.

#### 133 Data extraction, outcomes, and quality assessment

We conducted a narrative synthesis rather than meta-analysis because of the high degree of heterogeneity across studies in terms of their study design, outcomes, intervention and context. The studies were classified into four broad intervention categories, and the intervention activities, data collection methods, and primary outcomes extracted for each study.

Eligible studies were tabulated to document the direction, magnitude and significance of effects foreach reported primary outcome. The following primary outcomes were extracted and synthesized:

- 140 1. **ACT uptake:** The proportion of patients with a history of fever who received an ACT (or a 141 quality-assured ACT) (use), or the proportion of antimalarials dispensed that are ACT (or a 142 quality-assured ACT) (market share).
- 143 2. **RDT uptake:** The proportion of patients with a history of fever who received an RDT.

144	3.	Dispensing treatment according to test results: Typically, the proportion of patients who
145		received no antimalarial after a negative RDT result and the proportion of patients who
146		received ACT after a positive RDT result (though there was some variation in definitions used).
147	4.	Referral: The proportion of patients requiring referral by intervention protocol who were
148		appropriately referred; and the proportion of patients referred who completed the referral.
149	5.	Patient adherence: The proportion of patients dispensed ACT who completed the full dose as
150		directed.
151	6.	Antibiotic uptake: The proportion of patients with a history of fever that received an
152		antibiotic.
153	7.	Antimalarial quality: The proportion of antimalarials purchased or sold that passed medicine
154		quality control tests.
155	8.	Health outcomes: Any health-related outcomes including but not limited to mortality,
156		morbidity, recovery rates, further treatment-seeking, and post-treatment anemia.
157		
158	The m	ethodological quality of each study was assessed using an adjusted Downs and Black quality
159	assessi	ment instrument that was developed to appraise the quality of quantitative studies [24]. After
160	testing	various quality assessment tools, Downs and Black was chosen as the primary tool due to its
161	ability	to capture the wide range of study designs in this review. Minor adjustments were made to the

167 inform the narrative synthesis, with any concerns about specific studies noted in the results.

tool to better assess the range of studies included in this review, including the addition of questions

from the Effective Public Health Practice Project quality assessment tool for quantitative studies,

Drummond's checklist for assessing economic evaluations, and the Newcastle-Ottawa Scale for

assessing the quality of nonrandomised studies in meta-analyses (S2 Table) [25-27]. The quality

assessment for each study was conducted by two authors independently. The results were used to

162

163

164

165

166

7

168 The results were synthesized within each intervention category. Factors such as context, background, 169 the difference in participants, variations in interventions, quality of evidence, and outcomes were 170 considered to understand the differences in direction and size of effect across studies.

# 171 Choice of data source reported

172 The choice of data source for outcomes such as RDT uptake and medicines dispensed can have an important impact on study findings. Sources may include extracting data from registers or other 173 174 records that providers keep themselves (provider records), direct observation of provider activities by 175 research team staff present at the PMR, exit interviews with clients leaving a PMR, patient follow-up 176 surveys (where patients are telephoned or visited at home after their PMR visit), and cross-sectional 177 household and outlet surveys. The potential for a Hawthorne effect (where PMRs alter their behaviour 178 because they are being observed) or social desirability bias (where they record or state what they 179 believe are correct behaviours) are likely to be highest with provider records and direct observation, followed by exit interviews and outlet surveys, but lower for patient follow-up surveys or household 180 181 surveys. However, the potential for recall bias is likely to be highest in household surveys, which may 182 also be more susceptible to confounding by contextual changes in the health system e.g. public sector 183 stockouts. To take account of this in the results we note the data source whenever we describe 184 studies. Where a study has more than one data source for a given indicator we generally present exit 185 interviews (rather than direct observation or household surveys).

186

# 187 Results

### 188 Study Selection

A total of 2598 records were identified through the database searches, plus 4 records identified
 through other sources (Fig 1). After removing duplicates, 1466 records were screened by title and

abstract, and 168 full text records were assessed for eligibility. Of these 41 papers were included in
the review, relating to 34 distinct studies.

#### 193 Fig 1. PRISMA Flow Diagram

194 The studies were categorised into four groups based on intervention content and breadth: (i) 195 introducing and enhancing ACT use (with no RDTs) (12 studies); (ii) introducing and enhancing RDT 196 use (15 studies); (iii) integrated community case management (iCCM) of malaria, pneumonia and 197 diarrhoea (4 studies); and (iv) broader PMR strategies that included malaria treatment (3 studies). 198 The characteristics of included studies are summarised in Table 1. Study findings are presented in 199 Tables 2a and b. As the main outcome indicators are different for interventions with and without RDTs, 200 interventions without RDTs are presented in Table 2a and those with RDTs in Table 2b. The Supporting 201 Information provides detailed characteristics of each study (S3 Table), data collection methods (S4 202 Tables a and b), quality assessment of studies (S5 Table). It also includes heat maps which colour-code 203 the intensity of the intervention and intervention outcomes, in order to explore patterns of results 204 across studies (S6 Tables a and b).

#### 205 Table 1 Summary of study characteristics<sup>1</sup>

	Introducing	Introducing	Introducing	Broader	Total
	and	and	and	private sector	
	enhancing	enhancing	enhancing	strategies	
	ACT use	RDT and ACT	iCCM	including ACT	
	(without	use			
	diagnostics)				
	n=12 studies	n=15 studies	n=4 studies	n=3 studies	n=34 studies
Study design:					
Cluster randomised control trial	2	7	1	1	11
Individually randomised control trial	2	5	-	-	7
Pre and post without control	5	-	-	-	5
Pre and post with control	3	2	2	-	7
Interrupted time series with control	-	-	1	-	1
Post-intervention with control	-	1	-	2	3
Country <sup>2</sup> :					
Angola	1	-	-	-	1
Ghana	3	2	-	-	5
Kenya	3	5	-	-	8
Madagascar	2	-	-	-	2
Niger	1	-	-	-	1
Nigeria	3	4	-	-	7
Tanzania	5	1	-	2	8
Uganda	6	3	4	1	14
PMR type:					
Drug shop	4	11	4	2	21
Pharmacy	1	2	-	-	3
Drug shops and pharmacies	-	2	-	-	2
Any PMR	7	-	-	-	7
CHWs as retailers	-	-	-	1	1
Location:					
Rural	5	9	3	1	18
Urban (inc. peri-urban)	-	2	-	-	2
Rural and Urban (or peri-urban)	7	4	1	2	14

206 207

<sup>1</sup> Full details of characteristics of each study are provided in S3 Table

<sup>2</sup> 3 ACT subsidy studies covered multiple countries

208

Table 2a. Study outcomes - Introducing and enhancing ACT use (without diagnostics), and Broader private sector strategies including ACT - % (95% CI or SD) [SE]

Study D	Design	Outcomes <sup>1</sup>								
First author, Yr published; Country; Data source	Study Arms		ACT uptake		Antibiotic uptake	Patient adherence to treatment regimen	Medicine quality	Health outcomes		
		% febrile patients receiving ACT	% febrile patients receiving an antimalarial that received an ACT	% of antimalarial sales volumes that were ACTs	% of febrile patients that received an antibiotic	% of patients dispensed ACT who complete the full dose as directed	% of antimalarials purchased or sold that meet quality standards			
1. Introducing and enhancing	g ACT use (without diagnostic	:s)								
1.1 Sub-national ACT subsidy	programmes									
Kangwana 2011, 2013 <b>[28,</b> <b>29]</b> Kanya	Intervention: Subsidised paediatric ACTs	53.7 (12.3)* <sup>2</sup>	25.4 (6.9)* <sup>3</sup>			67.0 (8.5) <sup>2</sup>				
Household survey; mystery shopper survey (market share only)	Control: No subsidy	27.3 (15.2) <sup>2</sup>	1.8 (1.3) <sup>2, 3</sup>			49.4 (24.8) <sup>2</sup>				
Lussiana 2016 <b>[30]</b> Angola	Intervention: Subsidised paediatric ACTs			52.8 <sup>~4</sup>						
Outlet survey	Baseline: No subsidy			0.0						
Sabot 2009 <b>[31]</b> Tanzania	Intervention: Subsidised ACTs and RRP Intervention: Subsidised		70.8~ (<5 years) <sup>5</sup> 31.1~ (>5 years) 40.8~ (<5 years)	60.3*^ <sup>36</sup>						
survey (sales volumes)	Control: No subsidy		48.1° (>5 years) 6.3 (<5 years) 0~ (>5 years)	Negligible						
Talisuna 2012 <b>[32]</b> Uganda	Intervention: Subsidised ACTs	26.2* (23.2-29.2)	74.0			82.8~10				
Exit interview	Control: No subsidy	5.6 (4.0-7.35)	Not stated			Not stated				
1.2 National ACT subsidy pro	grammes					1				
ACTwatch 2017; IE Team 2012; Tougher 2012 <b>[12,</b>	Intervention: AMFm			51.8 <sup>*7</sup> (47.9-55.7)						
عم Ghana Outlet survey	Baseline: No subsidy			6.5 <sup>7</sup> (3.1-9.8)						

Study D	esign	Outcomes <sup>1</sup>									
First author, Yr published; Country; Data source	Study Arms		ACT uptake		Antibiotic uptake	Patient adherence to treatment regimen	Medicine quality	Health outcomes			
		% febrile patients receiving ACT	% febrile patients receiving an antimalarial that received an ACT	% of antimalarial sales volumes that were ACTs	% of febrile patients that received an antibiotic	% of patients dispensed ACT who complete the full dose as directed	% of antimalarials purchased or sold that meet quality standards				
Kenya	Intervention: CPM 2014			48.2* <sup>7,9</sup>							
Outlet survey	Intervention: AMFm			61.4* <sup>7</sup> (53.6-69.2)							
	Baseline: No subsidy			12.1 <sup>7</sup> (6.0-18.2)							
Madagascar	Intervention: CPM 2015			7.0* <sup>7,8,9</sup>							
Outlet survey (sales volumes); household survey	Intervention: CPM 2013			32.0* <sup>7,8,9</sup>							
(use)	Intervention: AMFm	8.4 <sup>*10</sup> (4.9-14.3)	44.5~ <sup>10</sup> (28.8-61.4)	22.0* <sup>7</sup> (12.9-31.0)							
	Baseline: No subsidy	3.4 <sup>10</sup> (2.0-5.7) <sup>0</sup>	7.2 <sup>10</sup> (4.4-11.5)	6.8 <sup>7</sup> (3.6-10.1)							
Niger Outlet survey	Intervention: AMFm			18.1* <sup>7</sup> (12.6-23.6)							
	Baseline: Subsidy			3.7 (1.2-6.2)							
Nigeria	Intervention: CPM 2015			35.0* <sup>7,8,9</sup>							
	Intervention: CPM 2013			27.0* <sup>7,8,9</sup>							
Outlet survey (sales volumes); household survey	Intervention: AMFm	11.1 <sup>*10</sup> (9.0-13.6)	30.3~ <sup>10</sup> (25.0-36.1)	17.8 <sup>*7</sup> (14.4-21.1)							
(use)	Baseline: No subsidy	4.4 <sup>10</sup> (3.5-5.6)	13.9 <sup>10</sup> (11.0-17.4)	2.2 <sup>7</sup> (1.2-3.2)							
Tanzania - Mainland	Intervention: CPM 2014			39.2* <sup>7,9</sup>							
Outlet survey (sales	Intervention: AMFm	33.7~10	61.5~ <sup>10</sup>	32.1* <sup>7</sup> (24-40.3)							
volumes); household survey (use)	Baseline: No subsidy	37.910	63.110	2.2 <sup>7</sup> (1.1-3.3)							
Tanzania – Zanzibar	Intervention: AMFm			60.7*7,9							
Outlet survey	Baseline: No subsidy			2.07							

Study [	Design	Outcomes <sup>1</sup>									
First author, Yr published; Country; Data source	Study Arms		ACT uptake		Antibiotic uptake	Patient adherence to treatment regimen	Medicine quality	Health outcomes			
		% febrile patients receiving ACT	% febrile patients receiving an antimalarial that received an ACT	% of antimalarial sales volumes that were ACTs	% of febrile patients that received an antibiotic	% of patients dispensed ACT who complete the full dose as directed	% of antimalarials purchased or sold that meet quality standards				
Uganda	Intervention: CPM 2015			47.5 <sup>7,8,9</sup>							
C	Intervention: CPM 2013			43.0*7,8,9							
Outlet survey	Intervention: AMFm	44.2 <sup>*10</sup> (37.7-50.8) <sup>0</sup>	82.6~ <sup>10</sup> (79.1-85.6)	38.5 <sup>*7</sup> (31.5-45.5)							
	Baseline: No subsidy	20.2 <sup>10</sup> (15.1-26.5)	40.1 <sup>10</sup> (31.0-49.9)	5.1 <sup>7</sup> (2.5-7.7)							
Fink 2013 <b>[34]</b> Uganda	Intervention: AMFm	47.5 <sup>*10</sup> (45.4-49.5)	65.3* (63.9 - 66.8)								
	Baseline: No subsidies	37.2 <sup>10</sup>	50.8								
Household survey		(34.7-39.7)	(48.9 – 52.8)								
Fiore 2018 <b>[35]</b> Pooled	Intervention: AMFm/CPM	9* <sup>20</sup>									
Household survey	Control: No subsidies	4 <sup>20</sup>									
Thomson 2014 <b>[36]</b> Tanzania	Intervention: AMFm	26.9*11	52.7 <sup>*11</sup>	34.0*12							
Outlet survey (sales volumes); household survey (use)	Baseline: No subsidy	18.511	30.611	2.2 <sup>12</sup>							
1.3 Interventions to enhance	user adherence to subsidise	d ACT									
Bruxvoort 2014 <b>[37]</b> Tanzania	Intervention: Text message reminders to PMR staff					68.3 (23.4)					
Client follow-up survey	Control: no text message reminders					<mark>69.8 (20.9)</mark>					
Cohen 2018 <b>[38]</b>	Intervention: Social										
Uganda	marketing packaging					61.1 [2.6] <sup>13</sup>					
	Intervention: stickers on										
Client follow-up survey	manufacturer's package					69.5 [3.0] <sup>13, 14</sup>					
	Control: Manufacturer's package					63.8					

Study	Design	Outcomes <sup>1</sup>									
First author, Yr published; Country; Data source	Study Arms		ACT uptake		Antibiotic uptake	Patient adherence to treatment regimen	Medicine quality	Health outcomes			
		% febrile patients receiving ACT	% febrile patients receiving an antimalarial that received an ACT	% of antimalarial sales volumes that were ACTs	% of febrile patients that received an antibiotic	% of patients dispensed ACT who complete the full dose as directed	% of antimalarials purchased or sold that meet quality standards				
Raifman 2014 <b>[39]</b> Ghana	Intervention: Long text message reminder to user					62.3 <sup>15</sup>					
Client follow-up survey	Intervention: Any text message reminder to user					57.1 <sup>15</sup>					
	Control: No text message					58.0 <sup>15</sup>					
4. Broader private sector str	ategies including ACT		-	_	-						
Bjorkman 2021 <b>[40]</b> Uganda	Intervention: Villages with CHWs as retailers	32.6 <sup>10, 13</sup>					90.6* <sup>13</sup>				
Household survey (use); mystery shoppers (medicine quality)	Control: Villages without	35.0 <sup>10</sup>					<b>73.7</b> <sup>13, 16</sup>				
Bjorkman 2019 <b>[41]</b> Uganda	Intervention: Villages with CHWs as retailers	67.2 <sup>~10, 13</sup>						13.45~17			
Household survey	Control: Villages without	66. <sup>10</sup>						19.4			
Thomson 2018 <b>[42]</b> Tanzania	Intervention: Areas with drug shop accreditation			41.6 <sup>18</sup>							
Outlet survey	Control: Areas without drug shop accreditation			25.118							
Briggs 2014 <b>[43]</b> Tanzania	Intervention: Areas with drug shop accreditation	<b>24.6</b> ~ <sup>13, 19</sup>			11.0~13, 19						
Exit interviews	Control: Areas without drug shop accreditation	16.6 <sup>13, 19</sup>			13.4 <sup>13, 19</sup>						

\* p<0.05 for significance of difference from control or baseline shown in table; \*^ p<0.05 for significance of difference from baseline data which is not shown; ~ significance not reported

<sup>1</sup>No studies were identified reporting on outcomes related to referral on the basis of protocol

212 <sup>2</sup> Outcome is measured among febrile children 3-59 months using AL.

213 <sup>3</sup> % of mystery shoppers dispensed AL.

<sup>4</sup>% of volumes sold that were subsidised AL. Comparison is from period without subsidised ACTs (2012) to a period with subsidised ACTs (2013).

<sup>5</sup>Outcome is not presented for all age groups combined.

216 <sup>6</sup> Measured among drug shops.

<sup>7</sup> Outcome is % of volumes sold that were quality-assured ACTs among all private for-profit outlets, including facilities.

218 <sup>8</sup> Approximate reading from figure

- <sup>9</sup> Statistical test is for change is from previous survey, not baseline.
- 220 <sup>10</sup> Outcome is measured among children <5
- <sup>11</sup>Outcome is measured among febrile patients that sought care at a specialised drug seller.
- 222 <sup>12</sup> Outcome is % of volumes sold that were quality-assured ACTs among specialised drug sellers.
- 223 <sup>13</sup> Author's calculation
- <sup>14</sup> Result are pooled for two versions of the sticker message. The sticker message "Malaria is not gone until..." had a larger effect on adherence.
- <sup>15</sup> Results shown for drug shop clients only. For all provider types adherence was 61.5% in the control group, 66.4% for the short text message and 64.1% for the long text message.
- 226 <sup>16</sup> % of incumbent drug shops selling ACT that passes quality testing.
- 227 <sup>17</sup> Outcome is under 5 mortality per 1,000 years of exposure.
- 228 <sup>18</sup>% of sales volumes in drug shops that were AL.
- 229 <sup>19</sup> Outcome is measured among drug shop clients
- 230 <sup>20</sup> Outcome is percent of children 0-59 months with fever that took private sector ACTs
- 231

## Table 2b. Study outcomes - Introducing and enhancing RDT and ACT use, and Introducing and enhancing iCCM - % (95% CI where available)

Stuc	ly Design	Outcomes										
First author, Yr published; Country; Data source	Study Arms	RDT uptake	ACT uptake	Antimalarial d	ispensing accordi	ng to RDT result		Antibiotic upta	ke	Patient adherence		
		% febrile patients at study outlet receiving RDT	% febrile patients receiving ACT	% patients with negative test not receiving antimalarial	% patients with positive test receiving ACT	% patients treated according to test result	% patients with negative RDT receiving antibiotic	% patients with positive RDT receiving antibiotic	% all febrile patients receiving antibiotic	% patients dispensed ACT who complete full dose		
2. Introducing and enha	ancing RDT and ACT use	•	•									
2.1 RDTs conducted by	PMRs		1	1			1	1	1	T		
Ansah 2015 <b>[44]</b> Ghana	Intervention: Trained providers and free RDTs	100 (provided to all)	47.2 <sup>2~</sup>	97	92 <sup>1</sup>	not stated	0.6	0	not stated	95		
Provider records; Follow-up survey (adherence only)	Control: Trained providers but no RDTs	(RDTs not available)	83.2 <sup>2</sup>							No sig. diff from intervention (% not stated)		
Cohen 2015 <b>[45]</b> Uganda	Intervention: Trained providers & subsidized RDTs	17.5 <sup>1</sup>	29.3 <sup>2</sup>	56.3	40.9	not stated	35 <sup>1</sup>	311	not stated			
Household survey; Study staff records (dispensing only)	Control: No intervention	9.9	not stated	not stated	not stated	not stated	not stated	not stated	not stated			
Maloney 2017 <b>[46]</b> Tanzania	Intervention: Trained providers and subsidized RDTs	67*^ (58–71)	32.4 <sup>2</sup>	90.8 <sup>2</sup>	84.4 <sup>2</sup>	not stated	10.5 <sup>2</sup>	15.6²	not stated			
Exit interviews	Intervention: Trained providers and unsubsidized RDTs	66*^ (59–72)	32.2 <sup>2</sup>	95.0 <sup>2</sup>	67.3 <sup>2</sup>	not stated	10.0 <sup>2</sup>	5.7 <sup>2</sup>	not stated			
	Control: No training or RDTs	3	43.2 <sup>2</sup>									
Mbonye 2015 <sup>8</sup> <b>[47]</b> Uganda	Intervention: Trained providers and subsidized RDTs	97.7	60.8	98.5 <sup>4</sup>	99.0 <sup>4</sup>	98.8 <sup>4</sup>	46.0 (Hopkins 2017)	23.6 (Hopkins 2017)	34.9* (Hopkins 2017)			
Provider records; Follow-up survey (antibiotics only)	Control: Trained providers but no RDTs		99.7						19.4 (Hopkins 2017)			
Dieci, 2023 <b>[48]</b> Kenya	Intervention: Patient subsidies - 90% RDT subsidy, 80% ACT subsidy	35.3* <sup>7</sup>	72.0* <sup>7</sup>	90.2*	90.8*							

Stud	Study Design		Outcomes										
First author, Yr published; Country; Data source	Study Arms	RDT uptake	ACT uptake	Antimalarial d	ispensing accordi	ng to RDT result		Antibiotic upta	ke	Patient adherence			
		% febrile patients at study outlet receiving RDT	% febrile patients receiving ACT	% patients with negative test not receiving antimalarial	% patients with positive test receiving ACT	% patients treated according to test result	% patients with negative RDT receiving antibiotic	% patients with positive RDT receiving antibiotic	% all febrile patients receiving antibiotic	% patients dispensed ACT who complete full dose			
Digital sales data	Intervention: Provider incentives - USD 0.86 for RDT, USD 0.76 for ACT with positive RDT, USD 0.29 for recording	27.7*7	77.6 <sup>7</sup>	89.3*	85.7*								
	Combined: Patient 60% RDT subsidy, 60% ACT subsidy; Provider incentive USD 0.14 for RDT, USD 0.14 for ACT with positive RDT, USD 0.29 for recording	27.9* <sup>7</sup>	73.1*7	82.2*	87.4*								
	Control: No intervention	8.17	86.7 <sup>7</sup>	24.2	67.9								
Omale 2021 <b>[49]</b> Nigeria	Intervention: Social group meetings + provider training	64.1* <sup>3</sup>											
Household survey	Intervention: Social group meetings	62.9* <sup>3</sup>											
	Control: No intervention	37.9 <sup>3</sup>											
Onwujekwe 2015 <b>[50]</b> Nigeria Results presented for	Intervention: Trained providers, subsidized RDTs, plus school intervention	8.4~²	55.9~²	13~²	71~ <sup>2</sup>	not stated	17~²	11~²	not stated				
PMRs only exc. public facilities <sup>3</sup>	Intervention: Trained providers and subsidized RDTs	12.3~ <b>2</b>	48.5 <sup>~2</sup>	43~ <b>2</b>	80~²	not stated	17~ <b>2</b>	15~ <b>2</b>	not stated				
Exit interviews; Provider records (test results)	Intervention: RDT demonstration and subsidized RDTs	24.8²	47.5 <sup>2</sup>	45²	76²	not stated	122	172	not stated				
Soniran 2022 [51] Ghana	Intervention: Trained providers and subsidized RDT	38.1 (NB low n=42)	33.3 (NB low n=42)	83.3 (NB low n=12)	not shown as n<10	not shown as n<10							

Stud	dy Design	Outcomes										
First author, Yr published; Country; Data source	Study Arms	RDT uptake	ACT uptake	Antimalarial d	ispensing accordi	ng to RDT result		Antibiotic upta	ke	Patient adherence		
		% febrile patients at study outlet receiving RDT	% febrile patients receiving ACT	% patients with negative test not receiving antimalarial	% patients with positive test receiving ACT	% patients treated according to test result	% patients with negative RDT receiving antibiotic	% patients with positive RDT receiving antibiotic	% all febrile patients receiving antibiotic	% patients dispensed ACT who complete full dose		
Mystery client survey	Control: No intervention	23.3 (NB low n=30)	53.3 (NB low n=30)	not shown as n<10	not shown as n<10	not shown as n<10						
2.2 RDTs conducted by	study staff											
Cohen 2015 <sup>14</sup> <b>[52]</b> Kenya	Intervention: Any ACT subsidy	20.0	41.5 (92% sub)* 35.1 (88% sub)* 36.8 (80% sub)* <sup>4</sup>	30 (92% sub)~ 40 (88% sub)~ 45 (80% sub)~ <sup>1</sup>	98 (92% sub)~ 98 (88% sub)~ 98 (80% sub)~1	not stated			13.9 (92% sub) 12.3 (88% sub) 8.5 (80% sub)* <sup>4</sup>			
Study staff records (RDT and	Intervention: Any RDT subsidy	29.1*	40.74	not stated	not stated	not stated			-			
antimalarials	Control: No ACT subsidy	21.4	19.0 <sup>4</sup>						18.5 <sup>4</sup>			
Household survey (any ACT, any antibiotic)	Control: No RDT subsidy	7.6	38.9 <sup>4</sup>						-			
Ikwuobe 2013 <b>[53]</b> Nigeria	Intervention: Free RDTs	100 (provided to all)	42.0 <sup>~7</sup>	48.4	85.7	not stated						
Study staff records	Control: No intervention	(RDTs not available)	70.7 <sup>7</sup>									
Laktabai 2020 <b>[54]</b> Kenya	Intervention: 50% RDT subsidy and 100% ACT subsidy	98.6* <sup>9</sup>	15.7~	94.9 <sup>4</sup>	77.4	92.2 <sup>4</sup>						
Study staff records (RDT); exit interviews (medicines	Intervention: 50% RDT subsidy and 67% ACT subsidy	100* <sup>9</sup>	23.7~	93.9 <sup>4</sup>	87.0	92.4 <sup>4</sup>						
dispensed)	Intervention: No RDT subsidy and 100% ACT subsidy	96.2	26.8~	93.5 <sup>4</sup>	92.2	93.2 <sup>4</sup>						
	Intervention: No RDT subsidy and 67% ACT subsidy	96.5	27.2	91.0 <sup>4</sup>	84.8	89.5 <sup>4</sup>						
Modrek 2014 <b>[55]</b> Nigeria	Intervention: Text messages to adult patients, free RDT and ACT	100 (provided to all)		76.9* <sup>5</sup>		79.8*5						

Stud	Study Design		Outcomes										
First author, Yr published; Country; Data source	Study Arms	RDT uptake	ACT uptake	Antimalarial d	ispensing accordi	ng to RDT result		Antibiotic upta	ke	Patient adherence			
		% febrile patients at study outlet receiving RDT	% febrile patients receiving ACT	% patients with negative test not receiving antimalarial	% patients with positive test receiving ACT	% patients treated according to test result	% patients with negative RDT receiving antibiotic	% patients with positive RDT receiving antibiotic	% all febrile patients receiving antibiotic	% patients dispensed ACT who complete full dose			
Follow-up survey	Control: Free RDT and ACT	100 (provided to all)		58.5 <sup>5</sup>		65.5 <sup>5</sup>							
Saran 2016 <b>[56]</b> Uganda Patient follow-up	Intervention: Free RDT and ACT subsidy									No sig. diff from control (% not stated)			
survey	Intervention: ACT subsidy									66.5			
2.3 RDTs conducted by	CHWs, with medicines provide	ed by PMRs		I	I		I	I	I	1			
O'Meara 2016 <b>[57]</b> Kenya	Intervention: Free RDT and 50% ACT subsidy	71.1~	43.9~	72.5 <sup>4</sup>	81.8*10	76.2 <sup>4</sup>							
CHW records (RDT); follow-up survey (medicines	Intervention: Free RDT and no ACT subsidy	67.0~	33.0~	80.0 <sup>4</sup>	71.4	77.6 <sup>4</sup>							
dispensed)	Intervention: No RDT subsidy and 50% ACT subsidy	42.5~	32.7~	87.1 <sup>*4, 9</sup>	84.0 <sup>*10</sup>	85.7*4							
	Intervention: No RDT subsidy and no ACT subsidy	42.0	29.0	92.6* <sup>4, 9</sup>	58.3	76.5 <sup>4</sup>							
O'Meara 2018 <b>[58]</b> Kenya	Intervention: Free RDT and ACT subsidy	55.0* <sup>3</sup>		70.14	90.0	88.5*4	47.3	25.2	22.6				
Household survey <sup>15</sup>	Control: No intervention	44.7 <sup>3</sup>		54.4 <sup>4</sup>	83.8	80.7 <sup>4</sup>	69.3	30.2	26.0				
3. Introducing and enh	ancing iCCM												
Awor 2014 <b>[59]</b> Uganda	Intervention: iCCM	87.7* (79.0–96.4)	80.7*	91.0 (NB low n=11)	100 (NB low n=33)	97.6	not stated	not stated	60*11				

Stu	dy Design	Outcomes										
First author, Yr published; Country; Data source	Study Arms	RDT uptake	ACT uptake	Antimalarial d	lispensing accordi	ing to RDT result	Antibiotic uptake			Patient adherence		
		% febrile patients at study outlet receiving RDT	% febrile patients receiving ACT	% patients with negative test not receiving antimalarial	% patients with positive test receiving ACT	% patients treated according to test result	% patients with negative RDT receiving antibiotic	% patients with positive RDT receiving antibiotic	% all febrile patients receiving antibiotic	% patients dispensed ACT who complete full dose		
Exit interviews (RDT uptake, medicines dispensed); Observation (dispensing by test result)	Control: No intervention	0	41.1				not stated	not stated	73.5 <sup>11</sup>			
Bagonza 2021 <b>[60]</b> Uganda	Intervention: iCCM with peer supervision					53.5-66.3 <sup>12</sup>						
Provider records	Control: Standard iCCM					47.1-67.1 <sup>12</sup>						
Kitutu 2017 <b>[61]</b> Uganda	Intervention: iCCM	47.8*	22.4	not stated	not stated	not stated <sup>13</sup>	not stated	not stated	not stated			
Exit interviews	Control: No intervention	0.39	14.3				not stated	not stated	not stated			
Mbonye 2020 <b>[62]</b> Uganda	Intervention: iCCM	86.9*	33.1*6	87.4	94.3*6	not stated	not stated	not stated	not stated			
Provider records	Control: No intervention	58.5	38.7 <sup>6</sup>	95.6	83.0 <sup>6</sup>	not stated	not stated	not stated	not stated			

\* p<0.05 for significance of difference from control or baseline shown in table; \* p<0.05 for significance of difference from baseline data which is not shown; ~ significance not reported

234 No studies were identified reporting on outcomes related to medicine quality or health outcomes. Only one study (Ansah et al)reported Referral according to protocol

235 <sup>1</sup> approximate reading from figure

236 <sup>2</sup> Not stated in original papers; taken from Visser et al review, based on Visser et al's contact with original study authors

<sup>3</sup> For Omale 2021 the indicator reported is "% febrile patients receiving RDT from any provider"; for O'Meara 2018 the indicator reported is "% febrile patients receiving any malaria test from any provider"

<sup>4</sup> For Laktabai 2020, O'Meara 2016 and O'Meara 2018 the indicator reported is "% patients with negative RDT not receiving ACT"; For Cohen 2015 (Kenya) and O'Meara 2018 results are reported from any

provider. For Mbonye 2015 the indicator reported is "% patients with negative RDT not receiving AL or rectal artesunate" and "% patients with positive test receiving AL or rectal artesunate"

<sup>5</sup> For Modrek 2014 the indicators reported are based on medicines taken by patients (not on those dispensed); the indicator "% patients with negative test not receiving antimalarial" is reported only for the 57%

241 of patients who bought both an antimalarial and drugs to treat their symptoms

<sup>6</sup> For Mbonye 2020 the indicators reported are "% all patients receiving AL" and "% patients with positive test receiving AL"

<sup>7</sup> For Ikwuobe 2013 the indicator reported is "% patients seeking to purchase antimalarials receiving ACT" rather than of all febrile patients. For Dieci 2023 the denominator for these indicators is "all people who

bought an antimalarial or an RDT"

<sup>8</sup> Also related studies by Hutchinson et al 2017 (including follow up survey findings), Hansen et al 2017

<sup>9</sup> Significance of difference between the subsidised RDT groups and the unsubsidised RDT groups, averaged across the price levels of ACTs

- <sup>10</sup> Significance of difference between the subsidised ACT groups and the unsubsidised ACT groups, irrespective of whether they received an RDT subsidy
- 248 <sup>11</sup> For Awor 2014 the indicator is reported out of all sick children, not just those with fever (though 98% of children reported fever)
- 249 <sup>12</sup> Bagonza 2021 used interrupted time series table includes range of results across 7 monthly post-intervention data points (no statistical difference in trend between intervention and control)
- 250 <sup>13</sup> Kitutu 2017 do not report this indicator but do report an alternative indicator of appropriate treatment for malaria (see text)
- 251 <sup>14</sup> Cohen 2015 Kenya results for the 11 treatment arms are not presented separately. Rather the effect of ACT and RDT subsidies is estimated by pooling arms in different combinations
- <sup>15</sup> Antibiotic uptake results for this study are available in both O'Meara 2018 and Laktabai 2022; we present the results from O'Meara 2018 as they relate to the final point of evaluation. The direction and size of
- 253 effects reported are similar in the two papers.
- 254
- 255

#### 256 We present the results by each of the four intervention categories.

# <sup>257</sup> Introducing and enhancing ACT use (without diagnostics)

The 12 studies on introducing or enhancing ACT use all included retail sector ACT subsidies. The findings are presented in 3 groups: evaluations of sub-national ACT subsidies (4 studies), national ACT subsidies (5 studies, of which 3 are multi-country), and interventions to improve adherence to subsidised ACT (3 studies) (Table 2a).

#### 261 Sub-national ACT subsidy programmes

262 Four evaluations were of sub-national ACT subsidies in Kenya, Uganda, Tanzania and Angola [28, 30-32]. All the projects started pre-AMFm, lasting 8 months to 3 years. The interventions were similar, involving an ACT subsidy 263 combined with branding of the subsidised product, behaviour change communications, PMR training (one day where 264 duration stated), and recommended retail prices (RRP). Kangwana et al (Kenya) and Lussiana et al (Angola) involved 265 266 subsidies of paediatric ACT only [28, 30], while Sabot et al (Tanzania) and Talisuna et al (Uganda) subsidised ACTs for 267 all age groups [31, 32]. In 3 studies, the subsidised ACTs were delivered directly to participating PMR, while in Sabot et al they were provided through a designated wholesaler. The studies covered a range of low, moderate and high 268 malaria transmission settings, with three in rural areas, and one covering urban and rural areas. The number of 269 participating PMRs ranged from 151 to 225 (not reported in one study). In all studies eligible PMR included drug shops 270 and/or pharmacies, while Kangwana et al also included general shops. Three studies were pre-post evaluations: of 271 272 these, two included a control group [31, 32], and one did not [30]. The fourth study was a cluster randomized control 273 trial [28].

There were large increases in ACT uptake across all studies with, for example, a 26.4 percentage point difference in febrile patients receiving ACT between the intervention and control arms in Kenya (household survey) [28], and a 20.6 percentage point difference in Uganda (exit interviews) [32]. In Tanzania the market share of ACT among PMR antimalarial sales was negligible in control areas and over 60% at endline (outlet survey) [31]. Where measured, these effects were observed across all socio-economic groups, with ACT uptake higher in intervention areas among all quintiles in Kenya [28], and even improving more among households with less education in Uganda [32]. Changes in

other outcomes relevant to this review were generally not measured, with the exception of patient adherence to ACT

dosing in Kenya, where the difference was not statistically significant (household survey) [28].

It was not possible to attribute variations in intervention effectiveness across studies to specific intervention components, due to the small number of studies, similarity of programmes, and differences in data collection methods (S6 Table a). The Tanzanian study implemented an RRP in one of the two intervention areas with mixed results: uptake was higher in the RRP area for children but not for adults, reflecting the finding that for adult doses the RRP appeared to have had the unintended effect of artificially inflating prices above the market rate [31].

#### 287 National ACT subsidy programmes

288 Five studies explored the impact of national ACT subsidy programmes – the AMFm and its successor the Co-Payment 289 Mechanism (CPM). The AMFm covered 7 African countries: Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, and 290 Tanzania (mainland and Zanzibar) from 2010-2012 [12]. It involved price negotiations with manufacturers, and subsidy 291 of quality-assured ACTs at the "factory-gate". Subsidised ACTs were imported by registered first-line buyers, and then distributed to PMRs through their usual distribution chains. Supporting interventions at country level involved some 292 293 combination of behaviour change communications, provider training, and RRPs, with considerable variation in their duration and scale across countries. Following a transition period in 2013, the CPM replaced AMFm in 6 countries 294 (Ghana, Kenya, Madagascar, Nigeria, Tanzania, Uganda), involving similar intervention components to AMFm. but with 295 differences in the source of funds, process of approving orders, and lower subsidy levels [8]. 296

Three studies assessed the impact of AMFm only, including the multi-country AMFm Independent Evaluation [12, 33], and two single country studies by Fink et al in Uganda and Thomson et al in Tanzania [34, 36]. Two later multi-country studies covered both the AMFm and CPM periods [8, 35]. The studies covered a range of low, moderate and high malaria transmission settings. Four of the studies were pre-post comparisons without control, while Fiore et al conducted a pre-post evaluation comparing countries with and without AMFm/CPM [35].

The studies found increases in the market share of quality-assured ACTs in private for-profit outlets across all countries implementing these subsidy programmes (outlet surveys). In the five countries with data from the CPM period (Kenya, Madagascar, Nigeria, Tanzania, Uganda) increased market share under AMFm was either sustained or rose further, except in Madagascar, where it increased substantially in the initial CPM period, but then fell to pre-AMFm levels [8].

The magnitudes of market share increases from pre-AMFm to the most recent data point were over 30 percentage points everywhere but Madagascar and Niger.

Data on the impact on ACT use from household surveys are somewhat more limited, and may also reflect concurrent 308 309 changes in public sector ACT provision. Pre-post data from Madagascar, Nigeria and Uganda show increases in ACT use among febrile children under 5, reflecting substantial substitution away from other antimalarials [33]. In Tanzania, 310 national data show a decrease in the percent of febrile patients receiving ACT overall following AMFm introduction 311 [33], but more detailed sub-national data indicate that this partially reflected reduced use of ACTs in public facilities 312 associated with an increase in diagnostic testing, while ACT use among patients visiting PMR increased [36]. Fiore et 313 al compared changes over time in ACT use among febrile patients that sought care in the private sector in AMFm/CPM 314 315 countries (Ghana, Nigeria, Uganda) and 12 comparator countries [35]. They found that AMFm/CPM increased use overall, but this seems to be mostly driven by improvements in Uganda. No other outcomes relevant to this review 316 317 were reported by these studies.

As with the sub-national pilots, there was no evidence that increases in ACT uptake were limited to certain socioeconomic groups. Increases in market share and use were similar in urban and rural areas [12, 35]; and where overall ACT use was shown to have increased (Madagascar, Nigeria, Uganda), this was also documented among children in the poorest two quintiles [33, 34]. However, in Nigeria the largest increases in market share were recorded among the top two quintiles [33].

It is challenging to identify the contribution of specific intervention components to performance (S6 Table a). For 323 324 example, Kenya and Tanzania had sustained implementation of communications activities and adherence to RRPs 325 seemed strong, and both countries saw large, sustained market share increases. However, large increases were also seen in Uganda, despite poor adherence to RRPs, and very limited behaviour change communications. The 326 Independent Evaluation attributed smaller market share increases in Madagascar and Niger during AMFm to low 327 ordering, political and economic disturbances, and the high proportion of general retailers among PMRs who may have 328 329 been viewed as less appropriate ACT sellers than pharmacies/drug shops [33]. However, much higher market share was achieved in Madagascar under the CPM in 2013 [8], indicating that their retail market composition was not 330 331 necessarily a barrier to higher ACT uptake.

#### 332 Interventions to enhance user adherence to subsidised ACT

333 Three RCTs evaluated interventions to improve adherence to the ACT dosing regimen (% patients dispensed ACT who 334 complete the full dose as directed). In Tanzania, Bruxvoort et al sent regular text messages to PMR staff to remind 335 them about the correct dispensing advice to give patients [37]. In Ghana, Raifman et al sent text messages to patients for 3 days after their visit to a facility or PMR to remind them to complete the full course, with patients randomly 336 allocated to receive either a long or short message [39]. In Uganda, Cohen et al modified the ACT packaging to provide 337 further information on adherence either through additional social marketing packaging or a simpler sticker attached 338 to existing packaging [38]. These were all short, focused interventions (2.5-5 months) involving 9-84 providers, in 339 moderate to high transmission settings, and in a mix of urban and rural, or rural only areas. Adherence was measured 340 341 at follow-up visits to patient in their homes.

Improvements in adherence either did not occur or were modest (less than 6 percentage points difference between intervention and control) across the three studies. In Uganda, the simpler sticker was found to be more effective than more complex social marketing packaging [38]. In Ghana, results from drug shops only showed no significant effect for either text message, though results for all provider types combined (drugs shops and facilities) indicated that the shorter text message improved adherence while the longer message did not [39].

## 347 Introducing and enhancing RDT and ACT use

15 studies were identified on introducing or enhancing RDT use in PMRs, all but one [51] of which either also included ACT subsidies or were conducted in the context of a national ACT subsidy programme. We present the studies in two groups: the first group covers 13 studies where RDTs were conducted at the PMR, while the second group covers 2 studies where community health workers (CHWs) conducted RDTs and provided vouchers for ACT purchase at PMRs in the same area [57, 58] (Table 2b).

#### 353 **RDTs conducted at PMRs**

Of the 13 studies where RDTs were conducted at PMRs, most involved drug shops with some including pharmacies. Reflecting very low routine RDT provision by PMRs in most settings, nine studies involved introduction of RDTs to PMRs where they were not previously used, while only 4 explored interventions to strengthen existing RDT use by

PMRs [45, 48, 49, 51]. The intervention package also involved ACT subsidies in 6 studies [47, 48, 52, 54-56], while in 5 of the remaining 7, AMFm or CPM subsidised ACTs were available in the market [44-46, 50, 53]. Eight studies tested an intervention package with PMR staff conducting the RDTs [44-51]; while in 5 studies the RDTs were conducted by research team members stationed at the PMR [52-56]. Of the latter group 3 studies generally had relatively short durations of 4 months or less (S5 Table).

For the 8 studies where PMR staff conducted the RDTs, the interventions involved PMR training (1-4 days) and 362 363 supervision (weekly, monthly or quarterly). In addition, Dieci et al tested the provision of performance incentives to 364 pharmacy staff for providing RDTs, providing ACT conditional on a positive test, and appropriate record keeping [48]. 365 Five studies included communications activities: Ansah et al, Mbonye et al and Soniran et al conducted community 366 meetings [44, 47, 51]; Omale et al tested sensitisation and education of women's and men's social groups [49]; and Onwujekwe et al included a school intervention [50]. In 5 studies RDTs were provided directly to PMRs by the study 367 368 team [44, 47, 48, 50, 51], in 2 studies PMRs purchased RDTs through designated wholesalers [45, 46], and in one study RDTs were obtained through regular distribution channels [49]. In one study RDTs were provided free to users [44]; in 369 most others RDTs were subsidised, except for Omale et al and one intervention arm in Maloney et al and Dieci et al 370 371 where no subsidy was provided [46, 48, 49]. The number of providers included varied from 7 [44] to 262 [46], and the 372 duration in months from 3 [49] to 17 [44]. All the studies were conducted in rural areas, while 3 also included urban 373 areas, and all in situations of moderate or high malaria transmission, except Dieci et al (mainly low transmission) [48]. All studies were cluster randomised trials, with the exception of Maloney et al and Soniran et al, which were pre-post 374 375 evaluations comparing intervention and control districts [46, 51].

376 The five studies where RDTs were conducted by research team members were not aiming to evaluate a comprehensive 377 RDT intervention package, but rather to test specific hypotheses about user behaviour in a small number of PMRs (ranging from 1-10 retailers). Laktabai et al and Cohen et al studied the impact of varying the level of RDT and ACT 378 379 subsidy, with for Laktabai et al the ACT subsidy being conditional on a positive RDT result [52, 54]. The other 3 studies in this group provided RDTs for free: Saran et al investigated whether having an RDT increased patient adherence to 380 the full treatment dose; Modrek et al investigated the effect of text message reminders on whether patients later 381 consumed the correct medicine for their RDT result; and Ikwuobe et al simply assessed medicines dispensed when an 382 383 RDT was conducted [53, 55, 56]. Three of these five studies were in rural and two in urban areas, and all under

384 moderate or high malaria transmission. Four studies individually randomised the intervention at the patient level, 385 while Ikwuobe et al compared one intervention and one control PMR [53].

#### 386 RDT uptake

RDT uptake refers to the percent of febrile patients at the outlet receiving an RDT. In 11 of the studies RDT uptake was zero or minimal in the absence of any intervention, but in 4 studies RDTs were already used, ranging from 8% of pharmacy clients in Kenya (digital sales records) [48], to 10% of drug shops in Uganda (household survey) [45], 23% of drug shops in Ghana (mystery shoppers) [51], and 38% of all providers in Nigeria (household survey - data not presented for PMR clients only) [49].

392 In two of the studies where PMRs conducted RDTs by Ansah et al and Mbonye et al, RDT uptake following the intervention was reported to be at or close to 100%, though both relied on the PMRs' own records, raising the risk 393 that staff will be more likely to record patients who were tested, or of other Hawthorne effects [44, 47]. For the 6 394 395 other studies where PMRs conducted RDTs, uptake in the intervention group was close to two thirds for Maloney et al (exit interviews) [46] and Omale et al (household survey) [49], close to one third for Dieci et al (digital sales data) 396 397 [48] and Soniran et al (mystery shoppers) [51], but under 20% for Onwujekwe et al (exit interviews) [50] and Cohen et 398 al Uganda (household survey) [45]. Two of the studies where research staff conducted RDTs reported on uptake based 399 on study team records, with results over 96% in Laktabai et al, but under 30% in Cohen et al [52, 54] (in Modrek et al, 400 Saran et al and Ikwuobe et al study staff provided RDTs to all intervention patients so uptake is not presented).

#### 401 **Dispensing according to test result**

402 Our standard definition of correct dispensing by RDT result was a patient with a negative test receiving no antimalarial, 403 and one with a positive test receiving an ACT, although there was variation in these indicators across studies. For example, some studies defined correct dispensing for negatives as not receiving ACT rather than not receiving any 404 antimalarial. Of the 9 studies reporting rates of correct dispensing for positive RDTs, Ansah et al and Mbonye et al had 405 very high rates of 92% and 99% respectively based on provider records [44, 47]. Rates over 80% were also seen in at 406 407 least one arm in 3 studies based on exit interviews [46, 50, 54], two studies based on study staff records [52, 53], and 408 one based on digital sales data [48], but Cohen et al reported a much lower rate of 41% based on household survey 409 data [45].

Of the 11 studies reporting rates of correct dispensing for negative RDTs, 5 reported rates over 90% in at least one arm including the two studies based on provider records [44, 47], two based on exit interviews [46, 54], one based on study staff records [52], and one based on digital sales data [48]. However, the other studies encompassed a wide range from 83% (mystery shoppers – though sample size very low) [51], to 77% (patient follow up survey) [55], 56% (household survey) [45], 48% (study staff records) [53] and 13-43% (exit interviews) [50]. Whether RDTs were performed by PMR or study staff did not appear to have a systematic effect on rates of correct dispensing for positive or negative RDTs (S6 Table b).

Ansah et al and Mbonye et al also assessed dispensing in relation to microscopy results based on samples collected at 417 418 the same time as the RDT test but examined at a later date in research team laboratories [44, 47]. As these data can 419 be presented for all patients regardless of whether they received an RDT, they can be used to assess targeting of medicines in the intervention and control/baseline in relation to true parasitological status. Both studies reported 420 substantially higher rates in the intervention than control arm of correct dispensing by microscopy results (slide 421 positive receives ACT and slide negative does not receive antimalarial), with significant differences of 47 percentage 422 points [44] and 39 percentage points [47] (data not presented in Tables). In the intervention arms rates of correct 423 424 dispensing by microscopy result were lower than when based on RDT result, despite extremely high RDT uptake in 425 these two studies. This reflected low specificity of RDTs compared to microscopy of 63% [47] and 70% [44] i.e. RDTs led to a high number of false positives. While this could partially reflect the detection of HRP2 antigen persistence by 426 RDTs, Ansah et al note that specificity was particularly low in three drug shops, raising the possibility that some PMRs 427 were incorrectly reporting positive RDT results to justify antimalarial sales [44]. 428

#### 429 ACT uptake

A comparison of ACT uptake (% all febrile patients receiving ACT) with and without RDT introduction was reported in 5 studies. While ACT uptake is not an indicator of quality of care as the latter depends on whether the patients are parasitaemic, ACT uptake is a useful indicator of potential savings in ACT from RDT introduction. Five studies showed substantially lower ACT uptake in the intervention arm compare to the control: Ansah et al of 83% v. 47% (provider records), Mbonye et al of 99.7 v. 61% (provider records), Ikwuobe et al of 71 v. 42% (study team records), Dieci et al of 87% v. 72-78% (digital sales data), and Soniran of 53% v. 33% (mystery shoppers) [44, 47, 48, 51, 53]. It was notable that Ansah et al, Mbonye et al and Dieci et al reported very high rates of ACT uptake in control arms without RDTs

(>83%). Maloney et al (exit interviews) and Cohen et al (household survey) showed no significant difference in ACT
uptake between arms, but the levels in their intervention arms (32% and 35-41% respectively) [46, 52] were lower
than in the intervention arms of the five studies showing large reductions.

#### 440 Other outcomes

Antibiotic uptake was reported in six studies post-intervention, for RDT negatives ranging from 0.6% (provider records) 441 [44] to 46% (provider records) (Mbonve et al, reported in Hopkins 2017 [63]), and for RDT positives from zero (provider 442 records) [44] to 31% (household survey) [45]. Only Mbonye et al reported on the difference in antibiotic uptake with 443 and without RDT introduction, which they found to be 15.5 percentage points higher in the intervention arm (Mbonye 444 445 et al, reported in Hopkins 2017 [63]). Two studies assessed the impact of RDT provision on patient adherence (% 446 patients dispensed ACT who completed the full dose) but neither found a significant impact (patient follow-up surveys) [44, 56]. Only one study reported the proportion of patients where a referral was required who were referred; by 447 448 protocol Ansah et al required that all RDT negatives were referred to health facilities, and they found that this occurred 449 in 80% of cases, of which 62% later reported that they went to the referral facility (patient follow-up survey – not 450 presented in Tables) [44]. Other studies reported overall referral levels but these are hard to interpret without knowing 451 whether referral was required. No studies reported on other review outcomes, or on variations in effectiveness by socio-economic status or urban/rural location. 452

#### 453 Impact of variation in RDT intervention design

The impact of variation in intervention design can be assessed either within studies with multiple intervention arms, or by comparing across studies with different intervention packages (Table 2b and S6 Table b). When comparing across studies, there is some indication that lower RDT retail prices were associated with higher RDT uptake. The three studies with very high RDT uptake provided RDTs free [44] or had relatively low RRPs or actual prices of USD 0.21 [54] and USD 0.23 [47], compared with USD 0.5 [45] and USD 0.69 [50] in two of the studies with low uptake (all prices converted to 2020 USD). By contrast, Cohen et al reported low uptake at a price of only USD 0.23 [52], but given that this was the earliest study identified (2009) low uptake could partially have reflected patients' unfamiliarity with RDTs.

461 Three studies assessed the impact of varying the RDT price as part of their study design. Maloney et al found no 462 difference in RDT uptake (exit interviews) between a subsidised RRP of USD 0.36 and unsubsidised of USD 0.75 [46].

463 Cohen et al found no substantive difference in RDT uptake when comparing free RDTs with those subsidised at USD 464 0.23, but a significant increase in RDT uptake from 7.6 to 29.1% (study staff records) when comparing any subsidy (free 465 or USD 0.23) with those unsubsidised at USD 1.51 [52]. In Laktabai et al a subsidised price of USD 0.21 compared with an unsubsidised price of USD 0.41 had limited impact as RDT uptake was over 96% in all arms (study staff records) 466 [54]. These varying results likely reflect the considerable variation in the level of the unsubsidised price across studies. 467 Two of these studies also explored variation in the ACT subsidy level. Laktabai et al found that varying whether ACT 468 469 was provided free or subsidised (conditional on a positive RDT) had no impact on RDT uptake or antimalarial dispensing, reflecting very high compliance with guidelines in all study arms (study staff records) [54]. Cohen et al 470

472 compared to the unsubsidised price of USD 7.48 [52]. Varying the ACT subsidy from 80 to 92% had no impact on 473 dispensing according to a positive RDT (which was high for all groups), but the lower ACT subsidy increased correct 474 dispensing for RDT negative patients (no antimalarial) (study staff records).

found varying the ACT subsidy from 80 to 92% had no impact on ACT uptake overall, although it substantially increased

471

Of the 6 studies where PMRs conducted the RDT there was some indication that interventions with higher training and supervision intensity had better dispensing outcomes [44, 47] (S6 Table b), but this could also have reflected outcome measurement based on provider records. Notably Maloney et al also reported high rates of appropriate dispensing (exit interviews) but had shorter training and less frequent supervision [46]. There was no clear pattern in RDT uptake across studies based on whether RDTs were directly delivered to PMRs by the study team (S6 Table b).

Four studies explored variations in other supportive measures across study arms, with two testing the impact of adding 480 481 provider training [49, 50], and one each the addition of social group mobilisation [49], a school intervention [50], text 482 message reminders to users [55], and provider performance incentives [48]. Omale et al found that the arm receiving social group mobilisation had higher RDT uptake (household survey) [49], and Modrek et al found that the arm where 483 patients received text messages reminding those RDT positive to take ACT and those RDT negative not to take any 484 485 antimalarials were significantly more likely to consume antimalarials in line with their RDT result (patient follow-up 486 survey) [55]. However, Onwujekwe et al found no evidence that adding provider training or a school intervention improved RDT uptake or dispensing (exit interviews) [50], and Omale et al found no difference in RDT uptake from 487 488 adding provider training to social group mobilisation (household survey) [49]. Dieci et al found no significant differences between 3 intervention arms comparing (i) patient subsidies for RDTs and ACTs (condition on a positive 489

- 490 test), (ii) provider performance incentives for appropriate RDT use, ACT provision and record keeping, and (iii) a
- 491 combined arm with both patient subsidies and provider incentives (digital sales data) [48].

#### 492 RDTs conducted by CHWs, with medicines provided by PMRs

493 Two studies by O'Meara et al, both in Western Kenya, used a different intervention model, where CHWs located close to PMRs were trained to conduct RDTs and provided vouchers for ACT purchase at PMRs for those patients with a 494 positive RDT result [57, 58]. Both studies were conducted in rural areas, with low or low to moderate malaria 495 transmission. The earlier study was a 12-month individually randomised trial with a factorial design involving 11 PMRs 496 497 [57]. Individuals with a malaria-like illness who had not yet sought treatment were recruited from their homes and 498 allocated to receive an unsubsidised or fully subsidised RDT by a CHW and one of two levels of ACT subsidy. The later study was a 20-month cluster randomised trial involving 42 PMRs, comparing community clusters with CHWs providing 499 free RDTs and conditional ACT subsidies with clusters where CHWs did not provide RDTs [58]. In both studies ACTs 500 were supplied to PMRs through the standard supply chain. No training or supervision on malaria case management 501 502 was provided to PMRs beyond a brief orientation on the vouchers and ACT dosing, but the later study included 503 community level communications activities [58].

O'Meara et al 2016 found that patients offered a free RDT had higher RDT uptake at CHWs, and higher malaria test 504 uptake overall (RDT or microscopy), with an adjusted difference of 18.6 percentage points (patient follow-up survey) 505 [57]. Receiving the conditional ACT subsidy did not lead to higher test uptake, but did increase dispensing in line with 506 a positive RDT result by 19.5 percentage points (patient follow-up survey) [57]. Appropriate ACT use following a test 507 was highest when clients paid for their RDT and were given a conditional voucher for their ACT. However, as RDT 508 uptake was low when they were unsubsidised, overall targeting of ACTs in all participants was highest in the groups 509 that received a free RDT. This analysis informed the design of the intervention for the cluster randomised trial, which 510 511 included a free RDT and conditional ACT subsidy [58]. Household survey data showed that at the community level this 512 intervention led to significantly better results in the intervention arm compared to the control arm for test uptake (55% v 45%), and correct dispensing for those with a negative RDT (70% v 55%), and with a positive RDT (90% v 84%) 513 [58]. The provision of antibiotics was slightly lower in the intervention arm (47% v 69% for RDT negatives; 25% v 30% 514 for RDT positives) (significance not reported). 515

## 516 Introducing and enhancing iCCM

Four studies were identified on introducing and enhancing iCCM in PMRs, all from Uganda (Table 2b). The iCCM interventions studied covered the treatment of children under 5 years for malaria (using RDT and ACT), pneumonia and diarrhoea. Three studies evaluated the introduction of iCCM [59, 61, 62], and a fourth the addition of peer supervision to an existing iCCM programme [60]. All four studies included drug shops in rural areas, with one also including private clinics and urban areas [62]. All studies were in areas of moderate or high malaria transmission, with the exception of Kitutu et al, where transmission was low to moderate [61].

The three studies of iCCM introduction included one cluster randomised trial [62] and 2 pre-post evaluations with control [59, 61], with the interventions involving PMR training (4-5 days), supervision (weekly to start, or monthly), and communications activities (eg radio, public meetings, shop branding, posters, leaflets, and/or training CHWs or Village Health Teams). Supplies, including ACTs and RDTs, respiratory timers, and medicines for pneumonia and diarrhoea were distributed directly to PMRs [59, 62] or through a designated wholesaler [61]. RDTs were provided free to users and ACTs were subsidised [59, 61]. The number of intervention providers ranged from 44 [59] to 61 [61], and the intervention duration from 9 [59] to 26 months [62].

The three studies introducing iCCM to PMRs all showed substantial increases in RDT uptake. Awor et al and Kitutu et 530 al had zero or negligible uptake in the control arm compared to uptake in the intervention arm of 88% and 48% 531 532 respectively (both exit interviews) [59, 61]. In Mbonye et al uptake was 59% in the control arm compared to 87% in 533 the intervention arm (provider records) [62]. Awor et al and Mbonye et al both reported very high rates of dispensing 534 on the basis of RDT result of 100% and 94% respectively for positive RDTs, and 91% and 87% for negative RDTs, though 535 these figures are based on direct observation [59] and provider records [62]. Kitutu et al did not report these indicators 536 but did find a substantial difference in a composite "appropriate treatment" indicator based on testing and dispensing 537 by protocol for both febrile and afebrile children between the intervention (57%) and control (1%) areas (exit interviews) [61]. The three studies report mixed findings on ACT uptake: Awor et al show substantially higher uptake 538 in the intervention arm (exit interviews) [59], Mbonye et al show significantly lower uptake (provider records) [62], 539 and Kitutu et al no difference (exit interviews) [61]. The effect on antibiotic use is reported by Awor et al only, showing 540 a significantly lower uptake by 13 percentage points (exit interviews) [59]. 541

The fourth iCCM study by Bagonza et al was an interrupted time series evaluation of the use of peer supervision to strengthen iCCM in 60 rural drug shops [60]. Selected PMR staff received a 3-day refresher training, and then made monthly visits to their peers for 8 months [60], while all products were provided by standard supply chains. The peer supervision had no impact on dispensing by test result (provider records) (the effect on other outcomes is not

546 reported).

- No iCCM studies reported other review outcomes or on variation in effectiveness by socio-economic status or urban /
   rural location.
- 549 Broader private sector strategies including ACT

Three studies were identified evaluating broader PMR interventions that included ACT provision. As none included 550 RDTs, the results are presented in Table 2a which shows studies involving ACT subsidies to facilitate comparison across 551 similar outcomes. Two studies evaluated the Accredited Drug Dispensing Outlet (ADDO) programme in Tanzania [42, 552 553 43], which had been implemented in rural and urban areas of 14 of Tanzania's 21 region at the time of the studies, 554 covering around 3.800 PMRs. The ADDO programme involved an initial PMR training of 35 days and regular 555 supervision. ADDOs were permitted to stock 49 prescription-only medicines, including ACT, which was subsidised through AMFm at the time of the studies. Both studies were post-intervention assessments comparing ADDO with 556 557 non-ADDO regions. Briggs et al covered one ADDO and one non-ADDO region, with moderate and low to moderate 558 malaria transmission [43], while Thomson et al was nationally representative covering areas with low, low to 559 moderate, and moderate transmission [42]. The studies found weak evidence that the ADDO programme improved 560 ACT uptake: Thomson et al found market share to be 42% in ADDO and 25% in non-ADDO regions based on outlet survey data though the difference was of borderline significance [42]. Briggs et al reported the proportion of febrile 561 562 patients obtaining ACT to be 25% in the ADDO region compared with 17% in the non-ADDO region (exit interviews) [43]. 563

The third study was a randomised controlled trial evaluating the establishment of the Living Goods model where, following a 2-week training, a cadre of CHWs were established as retailers in over 800 rural Ugandan villages with high malaria transmission, selling a package of health-related commodities including ACTs but not RDTs [41]. There was no evidence that the intervention improved ACT uptake (household survey) [40, 41]. However, it was found to have a

568 "spillover effect" of improving the quality of ACTs sold to mystery shoppers by incumbent drug shops in the villages 569 where the CHW retailers were located, with 91% of ACTs meeting quality standards in intervention villages, compared 570 with 74% in the control [40]. In addition, the programme was found to improve under 5-mortality (19.4/1000 in control 571 villages and 13.5/1000 in intervention areas), although this is likely due to the cumulative effect of the broader package 572 of products, given that ACT uptake did not increase (household survey) [41].

573

## 574 Discussion

This systematic review synthesises research findings across a wide range of interventions relevant to malaria case 575 576 management in PMRs in sub-Saharan Africa, providing a holistic view of the evidence base on policy options for retail 577 intervention. We adopted broader study design eligibility criteria than many systematic reviews, including studies with randomised and non-randomised control groups, and those with a baseline but no contemporaneous control. This 578 partly reflected a desire to be as inclusive as possible of available evidence, but also the fact that randomised or even 579 controlled designs may not be feasible or appropriate when evaluating large scale operational implementation of 580 581 interventions such as AMFm, where distribution through standard supply chains or use of mass media severely limits 582 the potential to restrict interventions to certain areas. We excluded studies that had neither a historical nor a contemporaneous control, though we recognise that uncontrolled cross-sectional studies can provide additional 583 584 insights, and we draw on some of these in this Discussion. Our review also excludes qualitative research, though we recognise that this is vital for understanding the reasons for intervention (in)effectiveness, and the broader intended 585 586 and unintended consequences. Geographical coverage of included studies was quite broad, covering urban and rural areas, and 8 countries, though the only evidence from Francophone West and Central Africa was one study covering 587 AMFm in Niger. This may present a barrier in terms of generalisability to the many high malaria burden countries in 588 these regions such as DRC, Mali, Burkina Faso and Cameroon. 589

We summarise here the key findings under each intervention category, and identify the outstanding evidence gaps, before turning to recommendations for future research. Beginning with ACT subsidy programmes and their supporting interventions, there is strong evidence that these increase the market share of quality-assured ACT, with the increase substantial in most settings. This has been demonstrated through both controlled small-scale studies, and the

evaluation of AMFm and CPM at national scale in multiple countries. Later studies have indicated that market share gains from AMFm were generally sustained even with lower CPM subsidy levels in most settings. Small-scale studies also provide strong evidence of increased ACT use based on household survey data. For national subsidy programmes household survey data are less complete and not so clear cut, but during AMFm ACT use increases were documented in 3 countries overall and among PMR users in a further one. There is also positive evidence on the equity of ACT subsidy programmes, with benefits experienced in both rural and urban areas, and among poorer groups.

A meta-analysis by Morris et al of the impact of ACT subsidies on private sector ACT use provided further support for 600 these conclusions, estimating that each USD 1 decrease in ACT price was linked to a 24 percentage point increase in 601 602 ACT use in the private sector, with no significant differences in this relationship when comparing the poorest vs richest 603 groups, rural vs urban populations or children vs adults [23]. Other cross-sectional studies not eligible for this review indicate that the coverage of ACT subsidies can vary across groups though this depends on context. Ye et al found that 604 605 the market share of AMFm-subsidised ACTs in private for-profit outlets was higher in remote than in non-remote areas in Ghana, but lower in remote areas in Kenya [64]. Tougher et al explored the impact by socio-economic group, finding 606 that in Nigeria use of subsidized ACTs from for-profit outlets was concentrated among the rich, while in Uganda it was 607 608 concentrated among the poor [65].

No interventions leading to substantial improvement in user adherence to ACT dosing regimens were identified, with adherence remaining at around two thirds in nearly all studies, indicating the range of factors beyond information that influence user behaviour [66]. RDT provision also did not improve adherence [44, 56].

612 Turning to the literature on RDT and iCCM provision, there are similarities between these two groups of studies, 613 although the iCCM studies are far fewer in number and all from Uganda. For both interventions most studies are smallscale pilots or experiments, with strong internal validity reflecting their individually or cluster randomized designs. 614 However, the interventions often include features not replicable under implementation at large scale, such as 615 providing ACT or RDT for free to PMRs and in some cases to users, direct distribution of commodities to PMRs, or 616 617 frequent supervision, and in several studies research team staff administering the RDTs (S5 Table). Despite these 618 limitations, one can draw a number of conclusions from this body of evidence. First provision of both RDT and iCCM 619 by PMRs is feasible. Secondly, in two studies under relatively controlled conditions, very high RDT uptake (over 97%) and dispensing by RDT result (over 92%) were found, though these studies relied on data collection methods likely to 620

621 be subject to substantial Hawthorne effects, such as PMRs' own records or direct observation. In studies under more 622 operational conditions and with methods less subject to Hawthorne bias, rates of RDT uptake of around two thirds 623 were found in some studies, though in others uptake was below 20%. The potential for reductions in price to increase 624 RDT uptake was mixed: reducing prices from high unsubsidised levels (USD 1.5 or above) to below USD 0.4 did 625 stimulate uptake, but demand was relatively insensitive to smaller changes in subsidised prices. High rates of dispensing by RDT result were demonstrated in most relatively operational settings, especially for RDT positive 626 patients where in all but one study over 80% obtained ACT. For RDT negatives, many studies found appropriate 627 dispensing rates over 77%, though in two studies this was under 50%. It was notable that all but one of the studies 628 testing RDTs in PMRs were conducted in moderate to high malaria transmission settings (S3 Table), though one might 629 630 expect RDT use to be particularly important in curtailing unnecessary ACT use in lower transmission settings. Similar 631 uptake and dispensing results were obtained where CHWs conducted RDTs and provided vouchers for ACT purchase at PMRs [57, 58]. This hybrid approach would only be feasible in settings with a substantial functional and sustainable 632 633 CHW network, and would require engagement and coordination across a wide range of stakeholders. No evidence was reported on the equity impact of RDT or iCCM introduction. 634

635 There was wide variation in rates of antibiotic dispensing to febrile patients in RDT and iCCM studies, from close to 636 zero to around a third, despite nearly all antibiotics being prescription-only medicines in most settings [7]. Managing antibiotic use is hampered by the lack of clear guidance on how non-malaria febrile illnesses should be 637 treated/referred by PMRs [10]. In particular, concern has been expressed that introduction of RDTs could lead to 638 639 antimalarials being substituted by antibiotics for RDT negatives, with overall increases in antibiotic use documented in many public sector settings [63]. Within this review two studies showed little change or a decrease in antibiotic 640 641 provision [58, 59], while one showed an increase (Mbonye et al, reported in Hopkins 2017 [63]), though it was not possible to assess for which patients antibiotics were warranted. 642

In marked contrast to the ACT subsidy literature, there were no eligible studies on RDT or iCCM implementation at large scale, with the biggest being Maloney et al, covering 2 districts in Tanzania [46]. This reflected a lack of eligible evaluations for some of the larger-scale RDT and iCCM initiatives in sub-Saharan Africa. A prominent example is the USD 20 million UNITAID-funded project to create private sector RDT markets in five African countries between 2013 and 2016 [67, 68]. In Kenya, Madagascar and Tanzania the implementing agency procured RDTs and provided a range

648 of services along the supply chain. In Nigeria and Uganda, both RDTs and ancillary services such as training, waste 649 management and demand creation were procured from manufacturers, and delivered through their networks of in-650 country importers and distributors. The project reportedly led to sales of 1.3-1.6 million RDTs, initiated regulatory 651 change in 3 countries and updated policies on RDT use in all countries, and was argued in the evaluation to have 652 fostered sustainable RDT markets in Kenva, Uganda and Tanzania, though not in Nigeria or Madagascar [67]. The UNITAID-funded team also drew on lessons from their project to produce a "Roadmap for optimizing private sector 653 malaria rapid diagnostic testing" in collaboration with WHO, providing detailed guidance on policy implementation 654 [69]. However, despite numerous data collection activities being undertaken, no evaluation meeting the inclusion 655 criteria for this review was available, partly reflecting a focus on "learning by doing" during implementation, and partly 656 657 the curtailment of funding before full scale-up. Other sizeable PMR projects without an evaluation eligible for this 658 review include Defeat Malaria in DRC which involved RDT provision through pharmacies; and MalariaCare's introduction of iCCM in drug shops in Nigeria [16]; while for the similar EQuiPP project in Nigeria, the evaluation is 659 660 only available in summary form with insufficient methodological detail for inclusion in this review [70].

Turning to the broader PMR interventions that covered a wider range of health conditions, the evidence base of 661 662 eligible studies was very limited, and no evaluations were identified of such interventions involving RDTs. The ADDO 663 programme has been implemented at national scale in Tanzania, with similar projects initiated in Ghana, Uganda and Liberia [71]. However, only two studies were identified with a baseline or control, both in Tanzania, providing some 664 665 evidence of increased ACT uptake. The Living Goods model of establishing CHWs as retailers did not improve ACT uptake, but did improve the quality of ACTs in the wider market. However, replicability has not been established in 666 other settings, and evidence was not available on more recent versions of the Living Goods model implemented at 667 large scale in Uganda and Kenya. 668

Only one of the evaluations eligible for this review employed any digital or online approaches for training, supervision, monitoring or surveillance of PMRs (Dieci et al used an existing digital sales and inventory management platform to deliver patient subsidies and provider performance incentives [48]). However, multiple digital tools are being developed, tested and implemented by NGOs and private tech companies in Africa, both specific to malaria and with broader remits [72, 73]. These can be classified into three broad groups:

37

674 PMR-facing – typically mobile app based, these include: (i) Mobile reporting of surveillance data from PMRs e.g. 675 Private Sector Integrated Surveillance System (ISS) piloted in ADDOs, and Uganda's mTrac tool [74], which both link to DHIS2; (ii) mobile-based detailing and training programmes e.g. PSI COVID training via WhatsApp; (iii) 676 677 Electronic point-of-sale (e-POS) systems, which provide a platform for PMRs to monitor their stock and support 678 re-ordering, and can also be used to monitor their practices in real-time, offer feedback, provide bulk discounts, deliver training messages, and target subsidies e.g. MaishaMeds (as used by Dieci et al [48]), Bloom, Shelf Life; (iv) 679 digital reading of RDTs that automates reporting of test results e.g. Audere's HealthPulse; and (v) clinical decision-680 681 support tools e.g. THINKMD's Medsinc, SHOPSPlus TB STARR, D-Tree International's Afya-Tek referral platform. Patient-facing – (i) online platforms or apps for generic or targeted health messaging e.g. Viamo, askNivi; (ii) apps 682 683 or card systems using mobile money to target subsidies to specific users or those testing positive e.g. mPharma's

684 Mutti card; (iii) digital platforms linked with insurance e.g. Babyl.

Regulator/supervisor-facing - tablet-based tools that facilitate in-person supervision or inspection e.g. PSI's Health
 Network Quality Improvement System (HNQIS).

Such digital tools are likely to be used in most retail interventions going forward, so the lack of evidence on their impact presents a challenge for policy makers, though it is anticipated that more data will be available in the near future. For example, the TESTsmART RCT in Kenya and Nigeria is evaluating conditional ACT subsidies and bonuses to PMR-staff delivered through a mobile app [75].

691 Another challenge in making policy decisions on the evidence base in this review is that ACT and RDT markets have changed considerably since the early phase of the review period, and this could have a substantial impact on 692 693 intervention effects. Of the interventions involving ACT subsidies with no RDTs, all the sub-national studies began pre-694 2010, and the baselines for the national AMFm/CPM studies were all pre-2012. These interventions started from a low 695 level of retail ACT sales, and guite high ACT retail prices. For example, in the AMFm countries, the baseline market share of quality-assured ACTs in private-for profit outlets was under 7% in all but one country [12], but in 2018/19 it 696 was 21% in Kenya, 30% in Nigeria and 50% in Uganda [76]. One might therefore expect a quality-assured ACT subsidy 697 programme introduced now to have smaller effects on ACT use than one introduced a decade ago. However, evidence 698 on the growing predominance of non quality-assured ACTs (i.e. not meeting international quality requirements) in 699 700 retail markets in recent years [77-79], indicates that subsidies could still play a role in increasing the market share of

quality-assured medicines. However, this may face resistance from those who fear this would crowd-out local
 manufacturers who lack the capacity to apply for pre-qualified status [18].

In addition to these developments in ACT markets, the policy environment has also changed over the course of the 703 review period, reflecting WHO's advocacy that all suspected malaria cases receive parasitological confirmation before 704 treatment [80]. This means that programmes to subsidise ACT in PMRs are unlikely to be supported without RDT 705 provision. The RDT market in PMRs has also expanded over the review period, though to a much smaller degree than 706 for ACTs. While there has been some increase in in RDT availability, the percentage of PMRs stocking RDTs has 707 708 remained well below 20% [6, 79], meaning that there is still considerable growth potential. It is likely that users are far 709 more familiar with RDTs than they were in the early period of this review, reflecting their use across the public sector 710 in recent years, which might increase user responsiveness to interventions to enhance RDT provision in PMRs. On the other hand, all but one of the RDT and iCCM interventions included in the review were implemented in the context of 711 subsidized ACTs, and the impact on RDT uptake and dispensing by test result in the absence of ACT subsidies is unclear. 712

In sum, important knowledge gaps remain, and an ongoing programme of evidence generation is needed to inform
 PMR interventions. We recommend that the research and policy agenda incorporate four key priorities:

715 First, evidence is needed on the impact of large-scale interventions to enhance the use of RDTs in guiding ACT use, covering multiple districts in a range of urban/rural, francophone/ anglophone, and endemicity settings. Given that 716 717 costs of ACT subsidies were US\$336 million for AMFm Phase 1 alone [12], it is likely that strategies using much lower commodity subsidies may be required. It is also important to recognise that approaches used in earlier studies such 718 719 as face-to-face training and supervision of all enrolled PMRs, may not be feasible given the sheer number of such 720 outlets and competing demands on health sector and regulatory staff. Rather these studies should test scalable and affordable models, incorporating "smart" approaches that benefit from substantial economies of scale, such as PMR-721 facing digital technologies for training, supervision, monitoring, stock control and surveillance; use of mass media; and 722 engagement with trade associations, importers and distributors. While these strategies are unlikely to be amenable 723 to RCT designs, other robust approaches to evaluation would be possible, and it is crucial that funders of such 724 725 interventions also support the generation and dissemination of this evidence, including the benefits of including the 726 high proportion of malaria cases seen at PMRs in national surveillance systems. Implementing these strategies will require changes in regulation at least for some countries and PMR types. In 2019 of 7 countries surveyed (Chad, DRC, 727

Ghana, Kenya, Nigeria, Tanzania, Uganda) RDTs could be administered in pharmacies in only 4 countries (DRC, Ghana, Nigeria, Uganda), while in registered drug stores in only 3 (Ghana, Nigeria, Uganda) [7]. Although it is recognised that illicit sales are common in some settings where they are not officially permitted [7], the lack of regulatory approval presents challenges for any intervention. However, expansion of point-of-care tests in PMRs for other conditions, including COVID-19, HIV and diabetes, may serve to shift the policy discourse. Similar considerations are relevant for evaluation of scale up of iCCM, which will likely also require adoption of scalable, smart intervention components.

Secondly, to enhance sustainability and government buy-in consideration should be given to the potential to integrate malaria and iCCM PMR strategies with broader health system developments, and wider private sector engagement strategies [81]. This may involve linking with PMR programmes for other health conditions such as TB [82] or family planning [83], or engagement with wider initiatives to strengthen PMR regulation and accreditation, medicine and diagnostic test regulation, antimicrobial stewardship, or social health insurance [19]. The limited evidence base on such broader strategies also highlights the necessity for such strategies to be tied to robust evaluation.

Thirdly, we propose a set of recommendations for future evaluations. First a standard set of core indicators should be 740 741 used in all evaluations going forward. Core indicators should include ACT and RDT uptake; dispensing of both 742 antimalarials and antibiotics by test status (positive, negative, no test); and referral according to guidelines. While we recognise that different authors may favour different precise definitions of these indicators, to enhance comparability 743 744 we propose that all studies at least report the primary outcomes specified for this review (see Methods). Further, we suggest that data from household surveys be broken down by treatment source (presenting for PMRs separately); that 745 metrics for ACTs are presented for both quality-assured and all ACTs; and that ACT and RDT availability and price are 746 747 also presented where feasible, to help understand the pathways to impact. We also recommend careful consideration 748 of the choice of data collection method; for example while use of routine paper-based PMR records may be lower cost, the Hawthorne effect may lead to substantial over-estimation of study outcomes. Where feasible, we also 749 suggest that evaluators consider including assessment of the accuracy of RDT results performed at PMRs, given that 750 751 the two studies in this review that conducted study blood slides found discrepancies that could signal significant false positive cases in PMRs [44, 47]. Given the importance of understanding equity of impact, we also recommend 752 measurement of the socio-economic status of users, for example using simplified asset indices [84]. 753

- 754 Fourthly, to consider the relative value for money of PMR strategies, policy makers require evidence on their predicted
- 755 cost-effectiveness. However, very few empirical cost and cost-effectiveness analyses of relevant interventions in sub-
- 756 Saharan Africa exist [48, 85-87]. Going forward, the need to gather additional empirical cost data should be noted,
- 757 together with the potential to use cost-effectiveness models to estimate outcomes such as the cost per death averted,
- and explore how these vary with intervention effectiveness and context [88-90].

759

760

761

# 762 Acknowledgements

- 763 We are grateful for the advice and review of earlier drafts from Andrea Bosman, Jane Cunningham, Peter Olumese
- 764 and Nicole Dagata.

## 765 Funding

766 This review was funded by the Global Malaria Programme of the World Health Organisation.

## 767 Author Contributions

- 768 All authors contributed to protocol development. Searches and screening were conducted by ST and TJS; data
- 769 extraction by ST, TJS and CG; and writing of first draft by CG and ST. All authors contributed to and reviewed the final

770 draft.

771

# 772 Supporting Information

- 773 S1 Table. Search strategy
- 774 S2 Table. Quality assessment checklist
- 775 S3 Table. Study and intervention characteristics
- 776 S4 Table. Study data collection methods
- 777 S5 Table. Quality assessment of included studies
- 778 S6 Table. Heat maps
- 779

## 780 References

781	1. World Health Organization. World malaria report 2021. Geneva: World Health Organization, Licence: CC BY-
782	NC-SA 3.0 IGO; 2021.
783	2. World Health Organisation. WHO Guidelines for the Treatment of Malaria, 2nd edition. Geneva: World
784	Health Organization; 2010.
785	3. WHO. Universal access to malaria diagnostic testing: an operational manual. Geneva: World Health
786	Organisation, https://apps.who.int/iris/handle/10665/44657 2011.
787	4. World Health Organization. World malaria report 2019. Geneva: World Health Organization, Licence: CC BY-
788	NC-SA 3.0 IGO; 2019.
789	5. Bradley SEK, Rosapep L, Shiras T. Where Do Caregivers Take Their Sick Children for Care? An Analysis of Care
790 791	Seeking and Equity in 24 USAID Priority Countries. Glob Health Sci Pract. 2020;8(3):518-33. Epub 20200930. doi: 10.9745/GHSP-D-20-00115. PubMed PMID: 33008861: PubMed Central PMCID: PMCPMC7541105
702	6 ACTwatch Group Hanson K. Goodman C. Testing times: trends in availability price, and market share of
702	malaria diagnostics in the public and private healthcare sector across eight sub-Saharan African countries from 2000
793	to 2015 Malar L 2017:16/1):205 Epub 20170510 doi: 10.1196/c12026.017.1920 5. DubMod DMID: 29526075.
794	DubMod Control DMCDMCE429572
795	<ul> <li>Publicieu Cellulai PiviciD. PiviciPivici3436375.</li> <li>Zurana TP, Couniban H, Olinga C, Esch K, Okita A, Dover S, et al. Analysis of policies and regulations that</li> </ul>
790	7. Kind and TK, Countrian H, Ollinga C, Esch K, Okita A, Poyer S, et al. Analysis of policies and regulations that
797	anect malaria case management in the private sector in Chau, Democratic Republic of Congo, Ghana, Nigeria, Kenya,
798	oganda and Onled Republic of Tanzania: working document prepared for the WHO technical consultation on
799	private sector case management of malaria in high burden countries, May 2019; 2019.
800	8. ACT watch Group, Tougher S, Hanson K, Goodman C. what happened to anti-matarial markets after the
801	Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African
802	countries under continuation of the private sector co-payment mechanism. Malar J. 2017;16(1):173. Epub 20170425.
803	dol: 10.1186/s12936-017-1814-z. Publied PMID: 28441956; Publied Central PMCD: PMCPMC5405529.
804	9. World Health Organization. A study on the public health and socioeconomic impact of substandard and
805	faisified medical products. Geneva: World Health Organization, Licence: CC BY-NC-SA 3.0 IGO; 2017.
806	10. Hopkins H, Bruxvoort K, Goodman C, Ansan EK, Yeung SM, Clarke S. Technical Brief: Malaria Case
807	Management in the Private Sector, 30 November 2016. Geneva: The Global Fund; 2016.
808	11. Goodman C, Brieger W, Unwin A, Millis A, Meek S, Greer G. Medicine sellers and malaria treatment in sub-
809	Sanaran Africa: what do they do and how can their practice be improved? Special issue: Defining and defeating the
810	intolerable burden of malaria III Progress and perspectives. 2007;77(6(Supplement)):203-18.
811	12. Tougher S, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, Goodman C, et al. Effect of the Affordable Medicines
812	Facility-malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based
813	combination therapies in seven countries: a before-and-after analysis of outlet survey data. Lancet (British edition).
814	2012;380(9857):1916-26. doi: <u>http://dx.doi.org/10.1016/S0140-6736(12)61732-2</u> .
815	13. Boulton I. Key learnings for malaria programme managers from AMFm Phase I. Geneva: Roll Back Malaria
816	Partnership,; 2013.
81/	14. Visser I, Bruxvoort K, Maloney K, Leslie I, Barat LM, Allan R, et al. Introducing malaria rapid diagnostic tests
818	in private medicine retail outlets: a systematic literature review. PLoS ONE. 2017;12(3):e0173093. doi:
819	<u>http://dx.doi.org/10.13/1/journal.pone.01/3093</u>
820	15. Awor P, Miller J, Peterson S. Systematic literature review of integrated community case management and
821	the private sector in Africa: relevant experiences and potential next steps. Themed issue: Current scientific evidence
822	for integrated community case management (ICCM) in Africa: findings from the ICCM evidence symposium.
823	
824	16. White J, Wadsworth AC, Clarence C, McCarten-Gibbs M. Case Management of Childhood Illness in the
825	Private Health Sector: A review of models of care and their effectiveness in reducing childhood diarrnea, malaria,
826	and pheumonia. December 2018 Rockville, MD: Sustaining Health Outcomes through the Private Sector (SHOPS)
827	Plus: Abt Associates Inc.; 2018.
020 020	17. Employ ivi, vialle-valentin C, Dillip A, Kiniyo B, Ivibwasi K, Semail IA, et al. Understanding the Kole of
029 020	ACCIENTED DUDY DISPENSING OUTLETS IN TAIL20110 S REGILLI SYSTEM. PLOS ONE. 2010;11(11):E0104332. EPUD 20101108.
03U 021	18 World Health Organization Meeting report of the WHO technical consultation on malaria case management
021 1C0	in the private sector in high-burden countries 1–2 May 2010, M/HO Headquarters, Conque, Switzerland, Conques
833	World Health Organisation, WHO/CDS/GMP/MPAC/2019.12; 2019.

834	19. Silverman R, Rosen D, Regan L, Vernon J, Yadav P. Malaria Case Management in the Private Sector in Africa:
835	A Call for Action to identify Sustainable Solutions, August 2021: Center for Global Development; 2021.
836	20. ACT watch Group, Phok S, Phanalasy S, Thein ST, Likhitsup A. Private sector opportunities and threats to
837	achieving malaria elimination in the Greater Mekong Subregion: results from malaria outlet surveys in Cambodia, the
838	Lao PDR, Myanmar, and Thailand. Malar J. 2017;16(1):180. Epub 20170502. doi: 10.1186/S12936-017-1800-5.
839	PubMed PMID: 28464945; PubMed Central PMCID: PMCPMC5414126.
840	21. Lussiana C. Towards subsidized malaria rapid diagnostic tests. Lessons learned from programmes to
841	subsidise artemisinin-based combination therapies in the private sector: a review. Health Policy Plan.
842	2016;31(7):928-39. Epub 20150409. doi: 10.1093/heapol/czv028. PubMed PMID: 25862732; PubMed Central PMCID:
843	PMCPMC4977424.
844	22. Bennett A, Avancena ALV, Wegbreit J, Cotter C, Roberts K, Gosling R. Engaging the private sector in malaria
845	surveillance: a review of strategies and recommendations for elimination settings. Malaria Journal. 2017;16(252).
846	dol: <u>http://dx.dol.org/10.1186/s12936-017-1901-1</u> .
847	23. Morris A, ward A, Moonen B, Sabot U, Conen JM. Price subsidies increase the use of private sector ACTS:
848 840	evidence from a systematic review. Health Policy Plan. 2015;30(3):397-405. Epub 20140314. doi:
849 950	10.1093/ Neapol/C20013. Publied PMID: 24633915; Publied Central PMCD: PMCPMC4353896.
850	24. Downs SH, Black N. The reasibility of creating a checklist for the assessment of the methodological quality
051	1008.52(6):277.84. doi: 10.1126/joch.52.6.277. DubMed DMID: 0764250: DubMed Control DMCD:
852 052	1998;52(6):377-84. doi: 10.1136/jech.52.6.377. Publyled PMID: 9764259; Publyled Central PMICID:
000 001	PIVICPIVICI/50/28.
0J4 055	Ovford University Press: 2021
822	26 EPHDP Quality Assessment tool for Quantitative Studies https://www.ephpp.ca/quality-assessment-tool-for-
850	20. EFTER: Quality Assessment tool for Quantitative Studies <u>https://www.eptipp.ca/quality-assessment-tool-toi-</u> quantitative-studies /: The Effective Public Health Practice Project
858	27 Wells GA Shea B O'Connell D Peterson I Welch V Losos M et al. The Newcastle-Ottawa Scale (NOS) for
850 850	assessing the quality of nonrandomised studies in meta-analyses
860	https://www.ohri.ca//programs/clinical_enidemiology/oxford.asp: Universities of Newcastle_Australia and Ottawa
861	Canada
862	28. Kangwana BP. Kedenge SV. Noor AM. Alegana VA. Nyandigisi AJ. Jayesh P. et al. The effect of an anti-malarial
863	subsidy programme on the quality of service provision of artemisinin-based combination therapy in Kenya: a cluster-
864	randomized, controlled trial. Malaria Journal. 2013:12(81).
865	29. Kangwana BP, Kedenge SV, Noor AM, Alegana VA, Nyandigisi AJ, Pandit J, et al. The impact of retail-sector
866	delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized
867	controlled trial. PLoS Medicine. 2011;8(5):e1000437. doi: http://dx.doi.org/10.1371/journal.pmed.1000437.
868	30. Lussiana C, Floridia M, Rosario JMd, Fortes F, Allan R. Impact of introducing subsidized combination
869	treatment with artemether-lumefantrine on sales of anti-malarial monotherapies: a survey of private sector
870	pharmacies in Huambo, Angola. Trans R Soc Trop Med Hyg. 2016;110(10):588-96. doi:
871	http://dx.doi.org/10.1093/trstmh/trw071
872	31. Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, Bishop D, et al. Piloting the global subsidy: the impact of
873	subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. PLoS
874	ONE. 2009;(September):e6857. doi: <a href="http://dx.doi.org/10.1371/journal.pone.0006857">http://dx.doi.org/10.1371/journal.pone.0006857</a> .
875	32. Talisuna AO, Daumerie PG, Balyeku A, Egan T, Piot B, Coghlan R, et al. Closing the access barrier for effective
876	antimalarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study.
877	Malaria Journal. 2012;11(356).
878	33. AMFm Independent Evaluation Team. Independent Evaluation of Phase 1 of the Affordable Medicines
879	Facility - malaria (AMFm), Multi-Country Independent Evaluation Report: Final Report. Calverton, Maryland and
880	London: ICF International and London School of Hygiene and Tropical Medicine.; 2012.
881	34. Fink G, Dickens WT, Jordan M, Cohen JL. Access to subsidized ACT and malaria treatment - evidence from the
882	first year of the AMFm program in six districts in Uganda. Health Policy Plan. 2014;29(4):517-27. doi:
883	http://dx.doi.org/10.1093/heapol/czt041.
884	35. Fiore J. The Impact of Subsidized Antimalarials on Treatment Seeking Behavior, Working Paper 1717, March
885	2018: Department of Economics, Tulane University; 2018.
886	36. Thomson R, Festo C, Johanes B, Kalolella A, Bruxvoort K, Nchimbi H, et al. Has Tanzania embraced the green
887	leaf? Results from outlet and household surveys before and after implementation of the Affordable Medicines
888	Facility-malaria. PLoS ONE. 2014;9(5):e95607. doi: <a href="http://dx.doi.org/10.1371/journal.pone.0095607">http://dx.doi.org/10.1371/journal.pone.0095607</a> .

889 890 891	37. Bruxvoort K, Festo C, Kalolella A, Cairns M, Lyaruu P, Kenani M, et al. Cluster randomized trial of text message reminders to retail staff in Tanzanian drug shops dispensing artemether-lumefantrine: effect on dispenser knowledge and patient adherence. Am J Trop Med Hyg. 2014;91(4):844-53. doi: <u>http://dx.doi.org/10.4269/ajtmh.14-</u>
892 893 894	<ul> <li>0126.</li> <li>38. Cohen J, Saran I. The impact of packaging and messaging on adherence to malaria treatment: evidence from a randomized controlled trial in Uganda. Journal of Development Economics. 2018;134:68-95. doi:</li> </ul>
895 896 897	<ul> <li><u>http://dx.doi.org/10.1016/j.jdeveco.2018.04.008</u>.</li> <li>39. Raifman JR, Lanthorn HE, Rokicki S, Fink G. The impact of text message reminders on adherence to antimalarial treatment in porthern Ghana: a randomized trial. PLoS One. 2014;9(10):e109032. Epub 20141028. doi:</li> </ul>
898 899	<ul> <li>10.1371/journal.pone.0109032. PubMed PMID: 25350546; PubMed Central PMCID: PMCPMC4211682.</li> <li>40. Björkman Nyqvist M, Svensson J, Yanagizawa-Drott D. Can Good Products Drive Out Bad? A Randomized</li> </ul>
900 901 902	Intervention in the Antimalarial Medicine Market in Uganda. Journal of the European Economics Association 2021;20(3):957-1000. doi: <u>https://doi.org/10.1093/jeea/jvab053</u> .
903 904	Experimental Evidence on Community Health Promoters in Uganda. American Economic Journal: Applied Economics. 2019;11(3):155–92. doi: <u>https://doi.org/10.1257/app.20170201</u> .
905 906 907	42. Thomson R, Johanes B, Festo C, Kalolella A, Taylor M, Tougher S, et al. An assessment of the malaria-related knowledge and practices of Tanzania's drug retailers: exploring the impact of drug store accreditation. BMC Health Services Research. 2018;18(169). doi: http://dx.doi.org/10.1186/s12913-018-2966-4.
908 909	43. Briggs MA, Kalolella A, Bruxvoort K, Wiegand R, Lopez G, Festo C, et al. Prevalence of malaria parasitemia and purchase of artemisinin-based combination therapies (ACTs) among drug shop clients in two regions in Tanzania
910 911 912	<ul> <li>44. Ansah EK, Narh-Bana S, Affran-Bonful H, Bart-Plange C, Cundill B, Gyapong M, et al. The impact of providing rapid diagnostic malaria tests on fever management in the private retail sector in Ghana: a cluster randomized trial.</li> </ul>
913 914	The BMJ. 2015;350(H1019). 45. Cohen J, Fink G, Maloney K, Berg K, Jordan M, Svoronos T, et al. Introducing rapid diagnostic tests for malaria
915 916 917	<ul> <li>http://dx.doi.org/10.2471/BLT.14.142489.</li> <li>Maloney K, Ward A, Krenz B, Petty N, Bryson L, Dolkart C, et al. Expanding access to parasite-based malaria</li> </ul>
918 919	diagnosis through retail drug shops in Tanzania: evidence from a randomized trial and implications for treatment. Malaria Journal. 2017;16(6). doi: <u>http://dx.doi.org/10.1186/s12936-016-1658-y</u> .
920 921 922	47. Mbonye AK, Magnussen P, Sham L, Hansen KS, Cundill B, Chandler C, et al. A cluster randomised trial introducing rapid diagnostic tests into registered drug shops in Uganda: impact on appropriate treatment of malaria. PLoS ONE. 2015;10(7):e0129545. doi: <u>http://dx.doi.org/10.1371/journal.pone.0129545</u> .
923 924 925	<ul> <li>48. Dieci M, Gertler P, Kolstad J. Using Patient Versus Provider Incentives to Improve the Diagnosis and</li> <li>Treatment of Malaria: University of California Berkeley, Working Paper, February 27, 2023; 2023.</li> <li>49. Omale LIL Azuogu BN. Alo C. Madubueze LIC. Oka OLL Okeke KC. et al. Social group and health-care provider.</li> </ul>
926 927	interventions to increase the demand for malaria rapid diagnostic tests among community members in Ebonyi State, Nigeria: a cluster-randomised controlled trial. Lancet Global Health. 2021;9(3):e320-e30. doi:
928 929 930	http://dx.doi.org/10.1016/S2214-109X(20)30508-8.50.Onwujekwe O, Mangham-Jefferies L, Cundill B, Alexander N, Langham J, Ibe O, et al. Effectiveness of Provider and Community Interventions to Improve Treatment of Uncomplicated Malaria in Nigeria: A Cluster
931 932 032	Randomized Controlled Trial. PLoS One. 2015;10(8):e0133832. Epub 20150826. doi: 10.1371/journal.pone.0133832. PubMed PMID: 26309023; PubMed Central PMCID: PMCPMC4550271.
933 934 935	malaria strategy among Over-the-Counter Medicine Sellers (OTCMS) through interventions implemented in selected rural communities of Fanteakwa North district, Ghana. Malar J. 2022;21(1):317. Epub 20221105. doi:
936 937 938	<ul> <li>10.1186/s12936-022-04338-9. PubMed PMID: 36335323; PubMed Central PMCID: PMCPMC9636763.</li> <li>52. Cohen J, Dupas P, Schaner S. Price Subsidies, Diagnostic Tests, and Targeting of Malaria Treatment: Evidence from a Bandomized Controlled Trial. Am Econ Rev. 2015;105(2):609-45.</li> </ul>
939 940	53. Ikwuobe JO, Faragher BE, Alawode G, Lalloo DG. The impact of rapid malaria diagnostic tests upon anti- malarial sales in community pharmacies in Gwagwalada, Nigeria. Malaria Journal. 2013;12(380).
941 942 943	54. Laktabai J, Saran I, Zhou Y, Simmons RA, Turner EL, Visser T, et al. Subsidise the test, the treatment or both? Results of an individually randomised controlled trial of the management of suspected malaria fevers in the retail sector in western Kenya. BMJ Global Health. 2020;5(11). doi: <u>http://dx.doi.org/10.1136/bmjgh-2020-003378</u> .

55. 944 Modrek S, Schatzkin E, Cruz Adl, Isiguzo C, Nwokolo E, Anyanti J, et al. SMS messages increase adherence to 945 rapid diagnostic test results among malaria patients: results from a pilot study in Nigeria. Malaria Journal. 946 2014;13(69). 947 Saran I, Yavuz E, Kasozi H, Cohen J. Can Rapid Diagnostic Testing for Malaria Increase Adherence to 56. 948 Artemether-Lumefantrine?: A Randomized Controlled Trial in Uganda. Am J Trop Med Hyg. 2016;94(4):857-67. Epub 20160229. doi: 10.4269/ajtmh.15-0420. PubMed PMID: 26928828; PubMed Central PMCID: PMCPMC4824230. 949 950 O'Meara WP, Mohanan M, Laktabai J, Lesser A, Platt A, Maffioli E, et al. Assessing the independent and 57. 951 combined effects of subsidies for antimalarials and rapid diagnostic testing on fever management decisions in the 952 retail sector: results from a factorial randomised trial in western Kenya. BMJ Global Health. 2016;1(2):e000101. doi: 953 http://dx.doi.org/10.1136/bmjgh-2016-000101. 954 O'Meara WP, Menya D, Laktabai J, Platt A, Saran I, Maffioli E, et al. Improving rational use of ACTs through 58. 955 diagnosis-dependent subsidies: Evidence from a cluster-randomized controlled trial in western Kenya. PLoS Med. 2018;15(7):e1002607. Epub 20180717. doi: 10.1371/journal.pmed.1002607. PubMed PMID: 30016316; PubMed 956 957 Central PMCID: PMCPMC6049880. 958 59. Awor P, Wamani H, Tylleskar T, Jagoe G, Peterson S. Increased access to care and appropriateness of 959 treatment at private sector drug shops with integrated management of malaria, pneumonia and diarrhoea: a quasi-960 experimental study in Uganda. PLoS ONE. 2014;9(12):e115440. doi: http://dx.doi.org/10.1371/journal.pone.0115440. 961 962 60. Bagonza A, Kitutu FE, Peterson S, Martensson A, Mutto M, Awor P, et al. Effectiveness of peer-supervision on 963 pediatric fever illness treatment among registered private drug sellers in East-Central Uganda: An interrupted time 964 series analysis. Health Sci Rep. 2021;4(2):e284. Epub 20210507. doi: 10.1002/hsr2.284. PubMed PMID: 33977166; PubMed Central PMCID: PMCPMC8103081. 965 Kitutu FE, Kalyango JN, Mayora C, Selling KE, Peterson S, Wamani H. Integrated community case 966 61. 967 management by drug sellers influences appropriate treatment of paediatric febrile illness in South Western Uganda: 968 a quasi-experimental study. Malaria Journal. 2017;16(425). doi: http://dx.doi.org/10.1186/s12936-017-2072-9. 969 62. Mbonye AK, Buregyeya E, Rutebemberwa E, Lal S, Clarke SE, Hansen KS, et al. Treatment of Sick Children Seeking Care in the Private Health Sector in Uganda: A Cluster Randomized Trial. Am J Trop Med Hyg. 970 2020;102(3):658-66. doi: 10.4269/ajtmh.19-0367. PubMed PMID: 31971139; PubMed Central PMCID: 971 972 PMCPMC7056412. 973 Hopkins H, Bruxvoort KJ, Cairns ME, Chandler CI, Leurent B, Ansah EK, et al. Impact of introduction of rapid 63. 974 diagnostic tests for malaria on antibiotic prescribing: analysis of observational and randomised studies in public and 975 private healthcare settings. BMJ. 2017;356:j1054. Epub 20170329. doi: 10.1136/bmj.j1054. PubMed PMID: 976 28356302; PubMed Central PMCID: PMCPMC5370398. Ye Y, Arnold F, Noor A, Wamukoya M, Amuasi J, Blay S, et al. The Affordable Medicines Facility-malaria 977 64. 978 (AMFm): are remote areas benefiting from the intervention? Malaria Journal. 2015;14(398). 979 65. Tougher S, Hanson K, Goodman CA. Does subsidizing the private for-profit sector benefit the poor? Evidence 980 from national antimalarial subsidies in Nigeria and Uganda. Health Econ. 2021;30(10):2510-30. Epub 20210722. doi: 981 10.1002/hec.4386. PubMed PMID: 34291524. 982 Banek K, DiLiberto DD, Webb EL, Smith SJ, Chandramohan D, Staedke SG. Exploring Barriers and Facilitators 66. of Adherence to Artemisinin-Based Combination Therapies for the Treatment of Uncomplicated Malaria in Children 983 in Freetown, Sierra Leone. Healthcare (Basel). 2021;9(9). Epub 20210918. doi: 10.3390/healthcare9091233. PubMed 984 985 PMID: 34575007; PubMed Central PMCID: PMCPMC8471195. Dalberg. Price subsidies increase the use of private sector ACTs: evidence from a systematic review, Final 986 67. 987 Report2016. 68. Poyer S, Musuva A, Njoki N, Okara R, Cutherell A, Sievers D, et al. Fever case management at private health 988 facilities and private pharmacies on the Kenyan coast: analysis of data from two rounds of client exit interviews and 989 990 mystery client visits. Malaria Journal. 2018;17(112). doi: <u>http://dx.doi.org/10.1186/s12936-018-2267-8</u>. 991 69. PSI. A roadmap for optimizing private sector malaria rapid diagnostic testing: Lessons learned from a multi-992 country pilot project in Africa: Population Services International; 2019. 993 70. MCSP. Improving Health Outcomes for Children Under Five in Nigeria, April 2019: Maternal Child Survival 994 Program, USAID; 2019. 995 Rutta E, Liana J, Embrey M, Johnson K, Kimatta S, Valimba R, et al. Accrediting retail drug shops to 71. 996 strengthen Tanzania's public health system: an ADDO case study. J Pharm Policy Pract. 2015;8:23. Epub 20150925. 997 doi: 10.1186/s40545-015-0044-4. PubMed PMID: 26413304; PubMed Central PMCID: PMCPMC4582893.

998 999	72. CHAI. Case Study: Scoping digital solutions for improving quality of care in the informal private sector 2022 [24/11/22]. Available from: <u>https://www.clintonhealthaccess.org/case-study/case-study-scoping-digital-solutions-</u>
000	for-improving-quality-of-care-in-the-informal-private-sector/.
001	73. Dagata N. Scoping digital solutions for improving quality of care in the informal private sector: Clinton Health
002	Access Initiative; 2021.
003	74. CHAI. Case Study: Expanding mTrac to Drug shops and Clinics in Uganda to Strengthen Integrated Malaria
004	Surveillance 2022 [24/11/22]. Available from: <u>https://www.clintonhealthaccess.org/case-study/case-study-</u>
005	expanding-mtrac-to-drug-shops-and-clinics-in-uganda-to-strengthen-integrated-malaria-surveillance/.
006	75. Woolsey AM, Simmons RA, Woldeghebriel M, Zhou Y, Ogunsola O, Laing S, et al. Incentivizing appropriate
007	malaria case management in the private sector: a study protocol for two linked cluster randomized controlled trials
008	to evaluate provider- and client-focused interventions in western Kenya and Lagos, Nigeria. Implement Sci.
009	2021;16(1):14. Epub 20210120. doi: 10.1186/s13012-020-010//-w. PubMed PMID: 334/2650; PubMed Central
010	PMCID: PMCPMC/816435.
011	76. CHAI. Research Blog Post: Sustaining a functioning market for malaria commodities 2022 [24/02/2023].
012	Available from: <a href="https://www.clintonnealtnaccess.org/research/sustaining-a-tunctioning-market-tor-malaria-">https://www.clintonnealtnaccess.org/research/sustaining-a-tunctioning-market-tor-malaria-</a>
013	<u>commodities/</u> .
014 015	77. ACT watch Group, Newton PN, Hanson K, Goodman C. Do anti-malariais in Africa meet quality standards? The
015	Diarket penetration of non-quality-assured artemisinin combination therapy in eight African countries. Malar J.
010	2017;10(1):204. Epub 20170525. doi: 10.1180/512930-017-1818-8. Publyled Pivild: 28539125; Publyled Central
017	PINCID. PINCPINC3444102. 78 Bosen D. Vernon I. Silverman R. Juma F. Dieci M. P. V. Malaria Case Management After the Affordable
010	Medicines Eacility for Malaria (AMEm): Availability, Quality, and Market Share for ACTs in Kenya's Private
015	Pharmacies Working Paper 561 December 2020 Washington DC: Center for Global Development: 2020
020	79 Edwards HM Sarwar R Mahmud P Emmanuel S Maxwell K Tibenderana IK The private sector market for
021	malaria rapid diagnostic tests in Nigeria: results of the 2018 market survey. Malar I, 2022;21(1):190 Epub 20220616
022	doi: 10 1186/s12936-022-04209-3 PubMed PMID: 35710474
024	80. World Health Organisation. Test, treat, track: scaling up diagnostic testing, treatment and surveillance for
025	malaria. Geneva: World Health Organisation: 2012.
026	81. World Health Organisation. Engaging the private health service delivery sector through governance in mixed
027	health systems: strategy report of the WHO Advisory Group on the Governance of the Private Sector for Universal
028	Health Coverage Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO.; 2020.
029	82. World Health Organisation. Public–private mix for TB prevention and care: a roadmap. Licence: CC BY-NC-SA
030	3.0 IGO. Geneva: World Health Organisation. Licence: CC BY-NC-SA 3.0 IGO.; 2018.
031	83. Lamba G, Shroff ZC, Babar ZU, Ghaffar A. Drug shops for stronger health systems: learning from initiatives in
032	six LMICs. J Pharm Policy Pract. 2021;14(Suppl 1):94. Epub 20211116. doi: 10.1186/s40545-021-00374-z. PubMed
033	PMID: 34784982; PubMed Central PMCID: PMCPMC8594096.
034	84. Chakraborty NM, Fry K, Behl R, Longfield K. Simplified Asset Indices to Measure Wealth and Equity in Health
035	Programs: A Reliability and Validity Analysis Using Survey Data From 16 Countries. Glob Health Sci Pract.
036	2016;4(1):141-54. Epub 20160325. doi: 10.9745/GHSP-D-15-00384. PubMed PMID: 27016550; PubMed Central
037	PMCID: PMCPMC4807755.
038	85. Goodman CA, Mutemi WM, Baya EK, Willetts A, Marsh V. The cost-effectiveness of improving malaria home
039	management: shopkeeper training in rural Kenya. Health Policy Plan. 2006;21(4):275-88. doi:
040	http://dx.doi.org/10.1093/heapol/czl011.
041	86. Hansen KS, Clarke SE, Sham L, Magnussen P, Mbonye AK. Cost-effectiveness analysis of introducing malaria
042	diagnostic testing in drug shops: a cluster-randomised trial in Uganda. PLoS ONE. 2017;12(12):e0189758. doi:
043	http://dx.doi.org/10.1371/journal.pone.0189758.
044	87. Lubogo P, Lukyamuzi JE, Kyambadde D, Komakech AA, Kitutu FE, Mulogo EM. Cost-effectiveness analysis of
045	integrated community case management delivery models utilizing drug sellers and community health workers for
046	treatment of under-five febrile cases of malaria, pneumonia, diarrhoea in rural Uganda. Malar J. 2021;20(1):407.
047	Epub 20211018. doi: 10.1186/s12936-021-03944-3. PubMed PMID: 34663345; PubMed Central PMCID:
048	
049	88. Bath D, Goodman C, Yeung S. Wodelling the cost-effectiveness of introducing subsidised malaria rapid
050	uiagnostic tests in the private retail sector in sub-sanaran Africa. Bivij Glob Health. 2020;5(5). doi: 10.1136/bmjgh-
021	2013-002130. PUDIVIEU PIVID. 52439090, PUDIVIEU CEITUAI PIVICID. PIVICPIVIC/24/415.

052 89. Ozawa S, Evans DR, Higgins CR, Laing SK, Awor P. Development of an agent-based model to assess the
impact of substandard and falsified anti-malarials: Uganda case study. Malar J. 2019;18(1):5. Epub 20190109. doi:
10.1186/s12936-018-2628-3. PubMed PMID: 30626380; PubMed Central PMCID: PMCPMC6327614.
055 90. Klein EY, Smith DL, Cohen JM, Laxminarayan R. Bioeconomic analysis of child-targeted subsidies for
ortemisinin combination therapies: a cost-effectiveness analysis. J R Soc Interface. 2015;12(107). doi:

057 10.1098/rsif.2014.1356. PubMed PMID: 25994293; PubMed Central PMCID: PMCPMC4590492.

.058



41 records included in review

# Figure